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In light of the major shift in HCV therapy resulting from the availability of highly potent 
direct acting antivirals (DAA), this study performed a surveillance of HCV coinfections 
among reported HIV new diagnoses in Germany. First the suitability of two commercial HCV 
ELISAs, Murex Ag/Ab (Abbott) and Monolisa Ag/Ab Ultra (Bio-Rad) for the detection of 
HCV in dried serum spots (DSS) was compared. The Murex ELISA was more sensitive in 
antigen positive plasma HCV seroconversion samples. In contrast, the Monolisa showed a 
higher sensitivity in HCV antibody positive DSS eluates. For this reason, samples from newly 
diagnosed HIV infections were examined using the Monolisa. Furthermore, an avidity test 
was established to distinguish between new and already longer existing infections. An optimal 
avidity index (AI) cut-off of 40% was determined for all genotypes, resulting in a period of 
364 days for classification as new HCV infection. To distinguish active and resolved 
infections, positive samples were analyzed by RT-qPCR and Western blot. Genotyping and 
identification of resistance-associated substitutions (RAS) was performed by sequence 
analysis. 
Of the total of 6,097 samples examined for the years 2015-2017, 396 were HCV ELISA 
reactive (6.5%). Of these, 256 (64.6%) were identified as active and 140 (35.4%) as resolved 
infections. A high proportion of HCV coinfections were observed in intravenous drug users 
(PWID, 77.8%, n=168/216), in the age group 30-39 years (9%, n=179/1,978) and in people of 
Eastern European origin (38.3%, n=124/324). Compared to 2016, the proportion of resolved 
infections in 2017 has increased in the total number of patients (p <0.01) and especially in 
people of foreign (p <0.01) and Eastern European (p <0.05) origin. HCV-subtypes (St)-1a, St-
3a, and St-1b were predominant with 33.9% (n=79/233), 33.5% (n=78/233) and 23.3% 
(n=52/233), respectively. In the samples from the diagnosis years 2015, 2016 and 2017, RAS 
were observed in a total of 69% (n=29/42), 60.8% (n=48/79) and 56.4% (n=22/39) samples, 
respectively. The proportion of St-1a and St-1b samples whose HCV sequence has resistance 
to DAAs was high in all diagnoses years (between 25% and 42.9%).  
The observed increase in the proportion of resolved HCV coinfections can be attributed to 
DAA therapy. However, further efforts are needed to ensure that groups with continued high 
HCV prevalence benefit from this treatment. The detection of RAS in samples of St-1a and 






In Anbetracht der enormen Verbesserung der HCV-Therapie durch die Entwicklung 
hochwirksamer und direkt wirkender Virostatika (DAA) dient diese Studie der Analyse von 
HCV-Koinfektionen unter den gemeldeten HIV-Neudiagnosen in Deutschland. Zunächst 
wurde die Eignung zweier kommerzieller HCV-ELISAs, dem Murex Ag/Ab (Abbott) und 
dem Monolisa Ag/Ab Ultra (Bio-Rad), zum Nachweis von HCV in getrockneten Serumspots 
(DSS) verglichen. Der Murex-ELISA zeigte sich sensitiver bei Antigen-positiven Plasma-
HCV-Serokonversionsproben. Dagegen zeigte der Monolisa eine höhere Sensitivität bei 
HCV-Antikörper-positiven DSS-Eluaten. Aus diesem Grund wurden Proben von neu 
diagnostizierten HIV-Infektionen unter Verwendung des Monolisa untersucht. Des Weiteren 
wurde ein Aviditätstest zur Unterscheidung von frischen und bereits länger bestehenden 
Infektionen etabliert. Für alle Genotypen wurde ein optimaler Aviditätsindex (AI) Cut-off von 
40% ermittelt, woraus ein Zeitraum von 364 Tagen für die Klassifizierung als frische HCV-
Infektion folgte. Um aktive und ausgeheilte Infektionen zu unterscheiden, wurden positive 
Proben mittels RT-qPCR- und Western-Blot analysiert. Die Genotypisierung und 
Identifizierung resistenzassoziierter Substitutionen (RAS) erfolgte mittels Sequenzanalyse. 
Von den insgesamt 6.097 untersuchten Proben der Jahre 2015-2017 waren 396 HCV-ELISA-
reaktiv (6,5%). Von diesen wurden 256 (64,6%) als aktive und 140 (35,4%) als ausgeheilte 
Infektionen identifiziert. Ein hoher Anteil der HCV-Koinfektionen wurde bei intra-venösen 
Drogenkonsumenten (PWID, 77,8%, n=168/216), in der Altersgruppe der 30-39 Jährigen 
(9%, n=179/1.978) und bei Menschen osteuropäischer Herkunft (38,3%, n=124/324) 
beobachtet. Im Vergleich zum Jahr 2016 hat sich der Anteil der ausgeheilten Infektionen im 
Jahr 2017 bei der Gesamtzahl der Patienten (p <0,01) sowie insbesondere bei Personen 
ausländischer (p <0,01) und osteuropäischer (p <0,05) Herkunft erhöht. Die HCV-Subtypen 
(St) -1a, St-3a und St-1b waren mit 33,9% (n = 79/233), 33,5% (n = 78/233) und 23,3% (n = 
52/233) vorherrschend. In den Proben der Diagnosejahre 2015, 2016 und 2017 wurden RAS 
in insgesamt 69% (n=29/42), 60,8% (n=48/79) und 56,4% (n=22/39) Proben detektiert. Der 
Anteil der St-1a- und St-1b-Proben, deren HCV-Sequenz gegen DAAs resistent ist, war in 
allen untersuchten Jahren hoch (25% - 42,9%).  
Der beobachtete Anstieg des Anteils der ausgeheilten HCV-Koinfektionen kann auf die DAA-
Therapie zurückgeführt werden. Es sind jedoch weitere Anstrengungen erforderlich, damit 
Gruppen mit weiterhin hoher HCV-Prävalenz von dieser Behandlung profitieren. Der 
Nachweis von RAS in Proben von St-1a und St-1b impliziert die weitere genaue 





1.1 Hepatitis C virus 
Hepatitis C virus (HCV) is the most common cause of chronic liver disease, cirrhosis, and 
hepatocellular carcinoma (HCC), as well as the main reason for liver transplantation 
worldwide. The virus was first isolated from the serum of a person with non-A, non-B 
hepatitis in 1989 (Choo et al., 1989).   
 
HCV is an RNA virus that is classified under the family flaviviridae (Lauer and Walker, 
2001). It replicates in the cytoplasm of hepatocytes and is not directly cytopathic. Persistence 
of the infection depends on rapid production of virus and continuous cell-to-cell spread, 
together with a lack of strong T-cell immune response to HCV antigens. HCV has a high 
turnover rate (1,010 to 1,012 virions per day) with a half life of 2-3 hours (Neumann et al., 
1998). Due to its rapid replication and the lack of error proofreading ability by the RNA 
polymerase, the genome mutates very often (Bukh et al., 1995). Currently, there are seven 
known genotypes (numbered 1 to 7) and more than 50 subtypes (NIHCDC, 2002). The 
frequent HCV mutations and the existence of various subtypes have rendered the search for 
an HCV vaccine difficult (Chen and Morgan, 2006). 
 
1.2 Epidemiology, transmission and natural History 
1.2.1 Global epidemiology of HCV infection 
According to the estimated report of World Health Organization (WHO), there are about 71 
million people living with HCV infection in the year 2015, which accounts for 1% of the 
population worldwide. The infection is not uniformly spread in different countries, with a 
prevalence ranging from 0.5% to 6.5%. The rate varies from 0.5% to 1.5% in Western 
countries and Australia reaching to 2.3% in South-east Asia and eastern Mediterranean 
regions, 3.2% in China, 0.9% in India, 2.2% in Indonesia and 6.5% in Pakistan (Petruzziello 
et al., 2016b) (Fig. 1). 
 
Since most acute infections are not detected clinically, it is hard to determine the rate of new 
HCV infections. As reported by Vogel et al (Vogel et al., 2009), less than 25% of the acute 
cases are clinically presentable. Moreover, the duration of infection can not be known at the 
time of diagnosis. However, it is estimated that the number of new infections has shown a 






Fig. 1: Global HCV prevalence (Blach et al., 2017). 
 
1.3 Routes of transmission  
1.3.1 Health-care-associated transmission 
In countries where infection control measures were not enough, HCV infection can be 
associated with the use of unsafe injection practices and procedures like surgery, dental care, 
unscreened blood transfusions and renal dialysis (Candotti et al., 2001, Prati, 2006, Mohsen et 
al., 2015, Dhiman et al., 2016). In the year 2010, worldwide, the use of unsafe injection 
devices for health care purposes was 5% (Pepin et al., 2013) and these unsafe injections 
would lead to almost 315,000 new infections every year (Pepin et al., 2014). Furthermore, the 
excessive use of injections (Simonsen et al., 1999) together with poor injection practices can 
lead to increased HCV transmission (WHO, 2018).    
 
1.3.2 Transmission among people who inject drugs 
Injection drug use (IDU) is the most commonly reported cause of acute HCV infection. It has 
been shown that most of the new infections are acquired in individuals who are involved in 
the use of illegal drugs. The prevalence of anti-HCV antibodies among people who inject 
drugs (PWIDs) can be up to 70% with a significant variation in different regions, risk 
behavior, socioeconomic status etc. suggesting the efficient transmission of the virus through 
blood contact (Sutton et al., 2008). HCV infection has also been related to the use of 
recreational drug use like methamphetamine in a sexual context or intranasal cocaine use, 
which might be because of blood on the shared straws or sniffing paraphernalia. This could 
partly indicate the recent increase of HCV in HIV positive men who have sex with men 





1.3.3 Blood transfusion 
In the past, blood transfusion or the use of blood product has been described as a major risk 
factor for HCV transmission. In some studies, more than 10% of the individuals who have 
received blood were infected (Alter et al., 1989). Nevertheless, the screening of blood 
donations since the beginning of 1990s has drastically decreased this transmission route. In 
high-income countries, blood donors are at least screened for the presence of anti-HCV 
antibodies and HCV RNA. The transmission risk is now estimated to be between 1:500,000 
and 1:1,000,000 units (Pomper et al., 2003). Before the introduction of HCV screening, more 
than 90% of patients in cohorts of multiply transfused patients were infected with the virus 
(Francois et al., 1993).      
 
1.3.4 Organ transplantation 
Individuals who have received organ transplants from HCV positive donors have a high risk 
of getting the infection. The rate of transmission has been shown to differ from 30% to 80% 
(Pereira et al., 1991, Roth et al., 1994). Therefore, most transplant organizations have devised 
strategies for screening and selection of organs from HCV positive donors (Mauss et al., 
2018).   
 
1.3.5 Other modes of transmission 
The other modes of transmission include mother-to-child transmission, which affects 4-8% 
and 10.8-25% of children who are born from women with HCV infection and HIV/HCV 
coinfection, respectively (Benova et al., 2014). Sexual transmission of HCV is rare in 
heterosexual couples. But, the infection mostly occurs in HIV-positive individuals, especially 
in MSM (WHO, 2018).  
     
1.4 Clinical manifestations of HCV infection 
1.4.1 Acute hepatitis 
By definition, acute hepatitis applies to the occurrence of clinical signs or symptoms of 
hepatitis for duration of 6 months or less after the initial exposure to HCV. In as early as 2 
weeks of acute infection, HCV RNA may become detectable in the serum/plasma (Blackard 
et al., 2008) (Fig. 2). Consistent with the course of acute hepatocellular injury, 
aminotransferases can become elevated in 6-12 weeks (range 1-26 weeks) and they may even 
be more than 10-30 times above the normal upper limit. Although the detection of antibodies 




However, the majority of the patients who have got the infection recently will be 
asymptomatic and have a clinically non-apparent or mild course. Symptoms of acute hepatitis 
include nausea, malaise and right upper quadrant pain. In patients who show these symptoms, 
the illness usually last for 2-12 weeks. After clinical resolution of the symptoms, the 
aminotransferases will normalize in about 40% of patients. HCV RNA can be lost in less than 
20% of patients indicating a cured infection. Fulminant hepatic failure due to acute HCV 
infection can happen in patients who have chronic hepatitis B (HBV) infection (Chu et al., 
1999). Unless otherwise the clinical suspicion is high, only few patients will be tested for 
HCV RNA or antibody seroconverion. Nevertheless, in the majority of infected patients, there 




Fig. 2: Changes in the blood titers of markers for HCV infection over time (Ahmad, 
2017). 
 
1.4.2 Chronic hepatitis 
In about 80% of HCV infection, the immune system is unable to completely eliminate the 




infection, it is considered chronic. At this stage of the disease, most patients are asymptomatic 
and there might not be symptoms such as myalgia, fatigue or arthralgia. The level of 
aminotransferases might be moderately increased or it can also be normal (Scott and Gretch, 
2007). The change in chronic infection is variable depending on factors such as higher body 
mass index, male gender, fatty liver, age of more than 40 years, coinfection by HIV and 
alcohol consumption (Thomas and Seeff, 2005). After 10 to 30 years, almost 10 to 20% of the 
patients develop cirrhosis. The cirrhosis may be related to liver failure, as decomposition after 
a portal hypertension (gastrointestinal bleeding, ascites, etc.). The risk of death due to 
complications of cirrhosis is 4% per year and the risk of having HCC is about 1 to 4% per 
year. Almost 39% of patients with HCC die within a year after its diagnosis (Thomas and 
Seeff, 2005, Scott and Gretch, 2007). In general, patients with cirrhosis have a five years 
survival rate of 50% (Morozov and Lagaye, 2018) (Fig. 3). 
 
1.4.3 Extrahepatic manifestations 
HCV infection can cause extrahepatic manifestations (Cacoub et al., 2016). The most 
common co-morbodities associated with HCV infected persons include depression, diabetes 
mellitus and chronic renal disease. These morbidities in some cases are directly caused by 
HCV and therefore can be referred to as extrahepatic manifestations. These manifestations are 
likely to be affected by treatment and their prevalence is usually independent of the stage of 








Fig. 3: Natural History of HCV Infection (Chen and Morgan, 2006). 
 
1.5 Viral structure and genome organization  
1.5.1 Viral structure 
HCV is an enveloped virus (Simmonds et al., 2012). It mainly replicates in the hepatocytes of 
infected patients (Wieland et al., 2014) and the replication was found to be dependent on the 
liver specific microRNA-122 (miR-122) (Jopling et al., 2005, Gottwein and Bukh, 2008). The 
nucleocapsid is formed by the viral genomic RNA associated with the capsid protein (core), 
which is spherical and about 30 nm in diameter (Fig. 4). The infectious virion comprises the 
nucleocapsid covered by a lipid-containing envelope which is derived from the host's 
endoplasmic reticulum (ER) membranes. The envelope has two glycoproteins E1 and E2, 
which are responsible for viral entry to hepatocytes through various host cell receptors 
(Douam et al., 2015). The virus particles which were generated in vitro and in vivo have a size 







1.5.2 Genome organization 
HCV has a single-stranded RNA genome which is about 9.6 kilo bases in length and encodes 
a single and large polyprotein of almost 3,000 amino acids. The polyprotein is cleaved after 
translation into many structural and nonstructural (NS) peptides. The structural components 
include 2 envelope glycoproteins (E1 and E2) and a nucleocapsid core (C). The NS proteins 
are labeled NS1 through NS5 (Major and Feinstone, 1997). The specific functions of each NS 
proteins have not been described in detail. NS3 has both protease and helicase activities, and 
the NS5 region has an RNA-dependent RNA polymerase activity for viral RNA replication. 
The enzymatic activities can serve as potential targets for antiviral drugs. The viral genome 
also has highly conserved 5' and 3' untranslated regions (Major and Feinstone, 1997, Honda et 
al., 1999, Kolykhalov et al., 2000). The 5' untranslated region (UTR/NTR) has a ribosomal 
entry site for initiation of viral protein translation. The 3' untranslated region has structured 
RNA elements, which are used for the purposes of viral replication and translation 








1.6 HCV Genotypes  
Advances in the analysis of sequences has resulted a remarkable increase in the number of 
publications with open reading frame (ORF) sequenced HCV isolates (Bukh, 2016). The 
phylogenetic analysis carried out by Smith et al (Smith et al., 2014) has confirmed the 
presence of 7 major genotypes and 67 subtypes, after which many additional subtypes have 
been confirmed (Li et al., 2014, Lu et al., 2015, Lu et al., 2016, Wang et al., 2019). Subtypes 
1a, 1b, 2a, 2b, 2c, 3a, 4a, 4d, 5a and 6a are clearly defined worldwide or in a certain groups in 
the population (Simmonds, 2013). The genomes of HCV isolates grouped into major 
genotypes differ by about 30% at the nucleotide and amino acid level while the subtypes can 
typically vary by up to 10%. Therefore, HCV has a high degree of genetic heterogeneity in its 
whole genome with important implications for treatment, diagnosis and development of an 
effective vaccine. Although naturally occurring intra- or intergenotypic recombinants are rare, 
the 1b/2k intergenotypic recombinant has spread and gained epidemiologic importance 
(Kalinina et al., 2002, Galli and Bukh, 2014).  
 
1.6.1 Global distribution of HCV genotypes 
The worldwide distribution of each HCV genotype differs in various geographical locations. 
HCV genotype 1 is the most common and has a wide geographical spread, representing 46% 
of all HCV infections. HCV genotype 3 is the next prevalent genotype which accounts for 
30% of global infections, and it is relatively common in Australia, south Asia, and in some 
countries in Europe. HCV genotypes 2 and 4 account for 9-13% of HCV infections and are 
limited in their global distribution. HCV genotype 2 has a higher prevalence in West Africa 
and Asia, while the incidence of HCV genotype 4 infection is higher in North Africa, central 
and eastern sub-Saharan Africa and the Middle East. HCV genotypes 5, 6 and 7 are restricted 
in their geographical distribution, with genotype 5 common in South Africa and genotype 6 
widespread in East and South-east Asia, while genotype 7 infections have been reported in 
very small proportions in individuals from the Democratic Republic of Congo (Gower et al., 







Fig. 5: Global distribution of HCV genotypes (Burstow et al., 2017). 
 
1.7 Diagnosis of HCV infection  
1.7.1 Diagnosing acute HCV  
1.7.1.1 Serological assays  
Using sera or plasma samples HCV infections can, in principle, be diagnosed by detection of 
viral antigen or antibodies using enzyme immunoassays (EIAs). The first generation of HCV 
EIAs was able to identify seroconversion with sensitivities typically not better than 80% and 
window periods of infectivity between 12 to 26 weeks. Moreover, some patients never 
seroconverted with these assays (Cao et al., 2011, Marwaha and Sachdev, 2014). By adding 
additional antigens the window period has been somewhat diminished to about 10 to 24 
weeks in the second generation EIAs and to 9-23 weeks in the third generation EIAs. A 
significant improvement resulted by the development of combination assays that detect two 
markers of the HCV infection, antigen and antibody. These sandwich ELISAs are designated 
as “fourth generation” or “antigen-antibody combo tests” and reach sensitivities of 100% and 
specificities of 99.5% (Brandao et al., 2013, Marwaha and Sachdev, 2014). With these assays 
the window period was further reduced by about 28 days and the combo tests considerably 
improved diagnosis in immunocompromised patients (Nastouli et al., 2009, Yang et al., 
2011). 
 
There are at least two broadly available commercial fourth generation ELISAs which can 
detect antigen (Ag) and antibody (Ab) simultaneously. These are the Monolisa Ultra Ag/Ab 
assay (Marnes-la-Coquette, France) and the Murex Ag/Ab combination assay (Abbott Murex, 




assay has been reported as more sensitive than the Monolisa assay using a panel of HCV 
window period samples, particularly in recognizing subtype 3a infections (Tuke et al., 2008).  
 
1.7.1.2 Molecular assays 
The measurable HCV RNA serum concentrations appear within few days after infection. For 
HCV RNA detection, qualitative sensitive assays with a lower detection limit of less than or 
equal to 50 IU/ml are required, for instance transcription-mediated amplification assay 
(TMA), qualitative RT-PCR or the newer real-time PCR systems. However, HCV RNA may 
vary during the phase of acute infection, making a second HCV RNA test mandatory several 
weeks later in all patients with a suspicion of acute HCV who tested negative. When HCV 
RNA is identified in seronegative patients, acute HCV is more likely. If patients are positive 
for HCV RNA and anti-HCV antibodies, it might be difficult to differentiate between acute 
and acutely exacerbated chronic HCV. The detection of anti-HCV IgM cannot distinguish 
between these possibilities because of its presence in both situations. In rare cases and 
especially when there is a low amount of inoculum, HCV infection may only be associated 
with a temporal HCV RNA detection or solely by markers of the innate immune response 
(Heller et al., 2013).      
 
1.7.2 Diagnosing chronic HCV  
Chronic HCV should be considered in patients who present morphological, clinical, or 
biological signs of chronic liver disease. When chronic HCV is suspected, testing for HCV 
antibodies by second and third generation EIAs is enough because their sensitivity is more 
than 99%. When anti-HCV antibodies are detected, the presence of HCV RNA has to be 
confirmed in order to distinguish chronic and resolved HCV infections (Mauss et al., 2018). 
 
1.7.3 HCV incidence assays 
The measurement of HCV incidence, the rate of newly infected cases in a population, is an 
essential epidemiological tool used to identify populations at risk and to monitor the impact of 
public health interventions at a population level (Deltenre, 2015). However, methods to 
estimate the incidence of HCV are challenging, primarily because HCV infection is frequently 
asymptomatic (Klimashevskaya et al., 2007, Gaudy-Graffin et al., 2010). Moreover, it is 
clinically important to differentiate recently acquired HCV infections from chronic infections 
and to identify primary infections that are asymptomatic. The only reliable laboratory means 




difficult to accomplish outside of prospective studies (Kanno and Kazuyama, 2002). 
However, prospective cohort studies are expensive, time-consuming, difficult to maintain, and 
prone to biases (Greenland, 1977, Cox et al., 2009). For discrimination between recent and 
long standing infections HCV antibody avidity assays can be used and applied for estimating 
HCV incidence rates using cross-sectional research data (Patel et al., 2016). It has previously 
been shown that HCV IgG antibody avidity, the binding capacity of maturing HCV-specific 
IgG antibody to antigen, increases progressively with time after exposure to an immunogen 
due to rapid mutations in the DNA coding for the variable part of the antibody (Inouye et al., 
1984). Therefore, the estimation of incidence from cross sectional surveys, using ‘incidence 
assays’ that distinguish ‘recent’ from ‘non-recent’ infections, have attracted a wide interest. 
 
1.7.4 HCV genotyping  
HCV genotyping can be done by using direct sequence analysis and reverse hybridisation 
technology. The first assays were designed to analyze only the 5'UTR, which causes a high 
rate of misclassification mostly at the subtype level. Current assays were improved by 
additionally analyzing the coding regions, particularly the genes which encode the non 
structural protein NS5B and the core protein, both of which show non-overlapping sequences 
between genotypes and subtypes (Bowden and Berzsenyi, 2006).  
 
1.8 Treatment of HCV 
1.8.1 Therapeutic management 
For more than a decade, the treatment of choice for HCV related chronic infection was the 
combination of pegylated interferon alpha (peg-IFN) and ribavirin (RBV), which provided a 
sustained viral clearance in half of the patients infected with genotype 1, and around 75% and 
60% of those infected with genotype 2 and genotype 3, respectively. Nevertheless, due to a 
non-satisfactory response, high severity and frequent side effects, the pharmaceutical 
companies were urged to develop more effective and well-tolerated drugs, termed Direct-
Acting Antivirals (DAAs), which have revolutionized the treatment of HCV infection. The 
interferon free treatment with DAAs offers a high chance for sustained HCV elimination and 
prevents the progression to liver disease. These new oral DAAs provide a sustained 
virological response (SVR) in almost 95% of the treated patients (Coppola et al., 2014, 
Coppola et al., 2015). As of May 2018, the Food and Drug Administration (FDA) had 
recognized 13 DAAs from four classes (Table 1) and many fixed dose combination (FDC) 









NS5B polymerase inhibitor 
(nucleotide analogue) 
NS5B polymerase inhibitor 
(non-nucleoside analogue) 
Glecaprevir Daclatasvir Sofosbuvir Dasabuvir 
Voxilaprevir Velpatasvir   
Grazoprevir Ledipasvir   
Paritaprevir Ombitasvir   
Simeprevir Pibrentasvir   
 Elbasvir   
 
1.8.2 Summary of the currently available pangenotypic DAA combinations 
DAAs are considered pangenotypic when they achieve high effectiveness in the treatment of 
all the main HCV genotypes (WHO, 2018). The suggested combination of pangenotypic 
DAAs for the management of HCV requires co-formulation with 2 and 3 second-generation 
DAAs. In so-called 'special populations' identified as HCV/HIV coinfection, chronic kidney 
disease (CKD), HCV/HBV coinfection and ineffective prior DAA regimens, these 
formulations have a strong antiviral potency (SVR >95%), good tolerance and decreased pill 
burden (Pol and Parlati, 2018). 
 
1.8.2.1 Sofosbuvir/Velpatasvir 
Sofosbuvir/Velpatasvir is a pangenotypic NS5A blocker of FDC. In clinical trials, it is 
associated with good effectiveness in genotype 1–6 infections, HIV/HCV coinfection, opioid 
replacement therapy (OST) patients and people with compensated and decompensated 
cirrhosis (Curry et al., 2015, Feld et al., 2015, Grebely et al., 2016, Wyles et al., 2017). 
 
1.8.2.2 Sofosbuvir/Velpatasvir/Voxilaprevir 
Sofosbuvir/Velpatasvir/Voxilaprevir is generally considered for treatment of HCV infected 
individuals who have previously failed the DAA regimen; however, certain high income 
countries also reported treatment-naïve HCV infected persons (WHO, 2018). 
 
1.8.2.3 Glecaprevir/Pibrentasvir 
Glecaprevir/Pibrentasvir is an FDC containing a pangenotypic NS3/4A protease inhibitor with 
a pangenotypic NS5A inhibitor. In clinical trials, Glecaprevir/Pibrentasvir has shown strong 




insufficiency and end-stage renal disease (Forns et al., 2017, Gane et al., 2017, Asselah et al., 
2018). It is contraindicated for individuals with decompensated cirrhosis (WHO, 2018). 
 
1.8.2.4 Sofosbuvir/Daclatasvir 
Clinical trials have shown strong efficacy of the combination of Daclatasvir and Sofosbuvir in 
genotype 1–4 infections, people with decompensated liver disease, liver transplant recipients 
and those with HIV/HCV coinfection (Lacombe et al., 2017, Rockstroh et al., 2017, Antonini 
et al., 2018). Data also show that the combination of Sofosbuvir/Daclatasvir is also useful in 
genotype 5 and 6 infections (Iwamoto et al., 2017). 
 
1.8.2.5 Other DAA regimens 
Additional evidence could suggest in the future that other DAA regimens (e.g. 
Sofosbuvir/Ravidasvir) are pangenotypic or that current pangenotypic DAA regimens may be 
used in more groups (e.g. children and teenagers < 18 years of age) (WHO, 2018). 
 
1.9 HCV resistance to DAAs 
The knowledge regarding the principles of how drug resistance viruses emerge is important 
during the use of antiviral therapies. HCV is a virus that replicates very quickly (billons of 
viruses/day) and the newly produced virus has an enzyme that results, on average, 1-3 errors 
per replication cycle. Most of these errors have no effect on viral progeny or result in a 
progeny that is non-replication competent (i.e. dead viruses). However, for some of the newly 
produced viruses, the transcription errors may result in the alteration of coding regions which, 
by chance, alter the susceptibility of the virus to one or more drugs used for the treating the 
virus. The emergence of these drug resistant viruses mostly occurs when drug levels are sub-
therapeutic, which eventually create a selective pressure for the resistant viruses to come out 
as dominant species. The newly produced resistant viruses have a selective advantage that 
helps them to grow and replicate in the presence of antiviral drugs. In some patients with 
chronic HCV infection, viral variants which contain substitutions associated with resistance to 
the HCV DAAs can be detected before the initiation of antiviral therapy. In the case of NS5A 
inhibitor containing regimens, this in particular may negatively affect treatment response. 
These kinds of substitutions are often called as baseline resistance associated substitutions 





Resistance viruses can also be selected and enriched in patients with DAA regimen failure. 
The substitutions that are contained in these viruses are designated as treatment emergent or 
treatment selected RASs. The RASs in NS3 and NS5A are frequently selected in patients who 
have a failure of NS3 and NS5A containing regimens, respectively. On the other hand, the 
selection of NS5B nucleotide RASs is rare (1% of failures) even after the exposure to a failing 
DAA regimen which contains a nucleotide inhibitor (Svarovskaia et al., 2014). This rare 
selection of RASs is due to the highly conserved catalytic site where the nucleotides bind, 
making the substitutions in this region very rare which is mostly referred to as a high barrier 
to resistance. Moreover, any of such substitution would likely cause the virus to become 
replication-incompetent. However, NS5A RASs can maintain the high viral replication 
competence (also called relative fitness) in the absence of continued drug pressure, which 
allows them to be the dominant viral quasispecies for many years in comparison to the NS3 
protease or NS5B nucleotide polymerase inhibitor RASs, which are relatively less fit and can 
disappear from peripheral blood within a few weeks to months, being dominated by the more 
fit and wild type virus species (AASLD, 2018). 
 
In general, drug specific RASs need to be present in at least 15% of the viruses of a given 
patient to reduce the likelihood of achieving SVR (Pawlotsky, 2016). Drug specific RASs that 
are found at a lower frequency may not convey sufficient resistance to lower SVR with 
currently available DAA regimens (AASLD, 2018).  
 
1.9.1 Therapeutic outcomes of DAAs against various HCV genotypes 
1.9.2 HCV-RAS in different genotypes 
The new DAA regimens achieve higher SVR rates in all genotypes, but the therapeutic 
efficacy varies at the level of genotypes as well as subtypes and even in more difficult to treat 
specific populations (e.g., HCV subtype 1a, genotype 3 and genotype 4 patients with 
compensated and decompensated cirrhosis, HCV/HIV coinfected patients, severe liver 
impairment patients and chronic kidney disease). DAA regimens individually, in combination 
(e.g. Sovaldi ®, Daklinza ®, Olysio ® with or without ribavirin) or as a fixed dose 
formulation (Epclusa ®, Harvoni ®, Zepatier ®, Viekira Pak ®, Vosevi ®, Mavyret ®) 
achieve higher SVR rates (> 95%) in treated patients with genotypes 1, 2, 5 or 6 infections. 
However, genotype 3 patients had SVR levels of ≤90–95%. Likewise, the viral rebound, 
virological breakthrough and the discontinuation of therapy were also common in cirrhotic 




It has also been shown that single or dual DAA regimens have not been able to achieve higher 
SVR rates in HCV genotype 3 patients and the addition of other DAAs (i.e. triple DAA 
regimens) is of importance to achieve higher SVR rates for this particular genotype. In 
clinical studies of approved regimens, HCV genotype 4 patients with or without cirrhosis also 
achieved compromised SVR rates (≤85–95%) (Shahid et al., 2018a). For this reason, the 
recently approved regimens are carefully recommended in compensated and decompensated 
cirrhotic patients. The mechanisms behind the variable reponses to all oral DAAs to various 
genotypes are not fully understood. However, high viral load, viral genome heterogeneity, 
disease progression and, in particular, the development of viral escape mutants are regarded as 
predisposing factors in this prospect (Buti and Esteban, 2016, Shahid et al., 2018a).     
 
1.9.3 Viral resistance substitutions against first-generation DAAs 
Patients who take Boceprevir or Telaprevir as monotherapy can develop antiviral resistance 
within a few days of treatment. In all HCV infected individuals, minor resistance populations 
to these drugs occur at baseline and are rapidly selected with Telaprevir or Boceprevir 
monotherapy (Jacobson et al., 2012). Likewise, prominent drug-drug interactions with many 
HIV antiretrovirals and calcineurin inhibitors also limit the clinical efficacy of Telaprevir and 
Boceprevir monotherapy (due to rapid emergence of RASs, severe drug adverse events and 
numerous possible drug-drug interactions, the first generation of potease inhibitors (PIs) have 
been suspended by the FDA to treat HCV patients in many parts of the world) (Susser et al., 
2011, Jacobson et al., 2012). R155 is the most important position in NS3/4A serine protease 
(a protein implicated in HCV translation and also a possible drug active site for the design and 
development of PIs) where various mutations can present resistance to almost all PIs (with the 
exception of MK-5172) (Romano et al., 2012). In vivo mutations at four locations 
(V36A/M/L, R155K/M/S/T, A156S/T and T54A) and one in vitro mutation (A156) have been 
observed and described against Telaprevir. Such mutations either individually (T54A, 
V36A/M, A156S, R155K/T,) or as double mutations (V36M + R155K, V36M + 156T, 
A156T/V) confer a low to high resistance to Telaprevir by modifying the active sites of 
NS3/4A serine protease (Welsch et al., 2008). The pattern of resistance to Telaprevir often 
differs considerably among different HCV subtypes. Clinical studies have shown that antiviral 
resistance is much more common in patients infected with subtype 1a than subtype 1b either 
using Telaprevir alone or together with PEG-IFN-α plus RBV (Susser et al., 2011). This is 
attributed to a single nucleotide polymorphism at position 155 in NS3/4A serine protease, 




(Welsch et al., 2008, Susser et al., 2011). Only a single nucleotide substitution is needed for 
HCV subtype 1a isolates to switch R to K at position 155, whereas 2 nucleotide changes are 
necessary for subtype 1b (Kliemann et al., 2016). Studies have also shown that subtype 1a has 
a higher fitness advantage than subtype 1b isolates, which is a predisposing factor in the 
production of viral escape mutants and viral breakthroughs to other sites within the NS3/4A 
catalytic subunit and other genomic regions of 1a isolates (Welsch et al., 2008, Susser et al., 
2011). 
 
1.9.4 RAS against second-generation DAAs 
Q80R/K polymorphism is responsible for low level resistance to Simeprevir. Clinical studies 
have predicted the existence of Q80K variants up to 50% in subtype 1a infected patients 
(approximately 20% in Europe and 50% in the US) and roughly 1% in subtype 1b isolates 
(Lenz et al., 2012). Lower SVR rates and gradual viral decline have been documented in 
subtype 1a patients treated with Simeprevir based triple therapy in Phase III clinical studies 
(20% lower in subtype 1a than 1b) (Manns et al., 2014). Q80K polymorphism and NS3 
genotype screening prior to therapy is highly recommended for patients with subtype 1a to 
prevent any adverse events, low virological response and discontinuation of treatment during 
therapy. The viral variants associated with NS3 PIs can detect a reverse transcription reaction 
by first synthesizing cDNA, followed by a PCR and a sequencing reaction. In the US, Quest 
Diagnostics ® and LabCorp ® developed Q80K polymorphism and viral variant screening 
against NS3 PIs (Lenz et al., 2012, Manns et al., 2014). 
 
1.9.5 Detection of resistance associated substitutions (RAS) 
The methods used for the detection of RAS include population sequencing (Sanger 
sequencing) and deep sequencing (next generation sequencing [NGS]). Both methods rely on 
sequencing of the viral RNA, assessing the amino acid sequence, and then inferring the 
existence of RASs. The sensitivity of the methods differ in detecting RASs. For the purposes 
of clinical care and making decisions with regards to which directly acting antiviral (DAA) 
regimen to use, these methods can be considered similar if a ≥15% cut-off is used for 
determining RAS by NGS. Studies have shown that NGS at a 1% level of sensitivity can 
result in the detection of additional RASs that are not related to clinical failure (Sarrazin et al., 





However, only few reference laboratories have made these tests available in the United States 
and Europe, and the performance of these assays has not been externally evaluated. In-house 
assays are available in some local laboratories, but their reliability and performance vary. The 
drug resistance testing for HCV is not trivial as it requires polymerase chain reaction (PCR) 
amplification of the three genes encoding the NS3 protease, NS5A and NS5B proteins. This 
can even be problematic especially for genotypes other than 1 and 4. Due to variation in the 
sensitivity of population sequencing, it can be difficult to interpret the results among 
laboratories, whereas the cutoffs for deep sequencing are not standardized. Not all RASs are 
clinically relevant and their effects relay on the proportion of viral quasispecies and the 
existence of other RASs in the same or other regions of the genome (Pawlotsky, 2016). 
 
1.10 HCV/HIV Coinfection 
1.10.1 Epidemiology of HIV/ HCV coinfection  
It is estimated that 4–5 million (11–14%) of the 35 million HIV-infected individuals 
worldwide are coinfected with HCV (Alter, 2006). Because HCV is transmitted mainly via 
blood-to-blood contact, the likelihood of coinfection depends on how HIV is transmitted. At 
the time of HIV diagnosis, most patients are already diagnosed with HCV. In Northern 
Europe, Canada and other regions where MSM is the predominant transmission group for 
HIV and preventive strategies for HIV and HCV are common for PWIDs, the prevalence of 
HCV coinfection is relatively low (5-20%), whereas in Eastern Europe, were PWIDs are the 
main driver of the HIV epidemic, the coinfection rates can be higher than 50% (Peters et al., 
2014) (Fig. 6). Although acute HCV outbreaks between HIV positive MSM have received 
considerable attention in recent years, the prevalence of HCV coinfection in this population 
remains relatively low. In EuroSIDA, a large pan-European longitudinal study that follows 
more than 13,000 patients with documented anti-HCV status infected with HIV, only 5% of 
MSM were coinfected with HCV. By contrast, 13% and 90% of people who describe 
heterosexual contact or IDU as their main risk of transmission of HIV are coinfected with 
HIV/HCV, respectively (Rockstroh et al., 2013). Because heterosexual transmission of HCV 
is rarely documented (Terrault et al., 2013), much of the high prevalence of coinfection in 
heterosexuals is likely explained by unreported transmission of IDU and iatrogenic HCV in 






     
Fig. 6: Prevalence of hepatitis C virus coinfection among HIV-infected people in 
individual countries (Peters and Klein, 2015). 
 
1.10.2 The situation in Germany 
A population based study in Germany found a 0.3% HCV antibody prevalence in the general 
population between the years 2008 to 2011. The actual prevalence of HCV antibodies may be 
higher as this study excluded hospitalized patients, psychiatric patients and prisoners. Also, 
there was an underrepresentation of other risk groups such as PWIDs and other populations at 
higher risk of HCV infection (Poethko-Muller et al., 2013). The study by Jansen et al (Jansen 
et al., 2015) was also Germany's first extensive screening of plasma samples from HIV 1-
positive MSM with documented date of HIV 1-seroconversion for HBV, HCV, and syphilis 
coinfection. In this study, 8.2% of the MSM were positive for HCV infection. Among these, 
10.5% were tested HCV positive at the time point of HIV seroconversion and 48.7% had 
HCV viremic test after HIV seroconversion. Genotype 1 was the most commonly found 
(71.6%), followed by genotypes 4 (19.2%), 3 (6.8%), and 2 (2.7%). As in other Western 
European countries, in Germany HCV is hyperendemic in PWIDs, and regional studies have 
found a prevalence of 50–80% in this transmission group (Stark et al., 1995, Stark et al., 




1.10.3 Natural history of HIV/HCV coinfection 
HIV coinfection adversely affects the course of infection with HCV. Coinfected individuals, 
especially those with advanced immunodeficiency (CD4 count <200 cells/mm3), have 
substantially increased progression to cirrhosis, decompensated cirrhosis and HCC compared 
with HCV-monoinfected individuals (Reiberger et al., 2010). In high-income countries, HCV 
associated liver disease has become the leading cause of death in HIV positive people, which 
accounts for nearly half (47%) of all deaths in the United States (Weber et al., 2006). It is not 
clear whether HCV infection fastens the progression of HIV disease, but compared to those 
with monoinfection, CD4 recovery in the coinfected individuals is impaired after initiation of 
antiretroviral therapy (ART) (Tsiara et al., 2013). In some studies, HIV/HCV coinfected 
individuals have shown a more rapid progression of HIV infection in relation to those who 
were HIV-infected alone (Rockstroh et al., 2005). Assessment of the effect of HCV infection 
on the progression of HIV infection may be confounded by the negative health consequences 
of IDU, which is strongly associated with HCV infection (May et al., 2015a). In persons with 
HIV coinfection, HCC tends to occur in people with HIV coinfection at a younger age and in 
a shorter period of time (Brau et al., 2007). 
 
1.10.4 Diagnosing HCV in HIV coinfection 
In rare cases of HCV/HIV coinfection, the detection of HCV antibodies can be lost during an 
advanced immune deficiency and does not necessarily indicate viral clearance (Cribier et al., 
1995). Therefore, a single negative HCV ELISA antibody does not necessarily exclude 
exposure to HCV in HIV-positive patients, particularly in severe immune deficiency. In 
addition, an increase in liver transaminases (especially Alanine aminotransferase, ALT) may 
be more sensitive for the detection of acute HCV in HIV positive patients than repeated tests 
for HCV antibodies (Thomson et al., 2009). However, in cases of suspected early acute HCV, 
the diagnosis based on HCV RNA is necessary.  
 
HCV RNAs are found in higher concentrations in HIV positive patients than HIV negative 
patients with HCV monoinfection (Perez-Olmeda et al., 2002). The levels of HCV viraemia 
can increase 8 times faster in HIV positive than HIV negative patients. The highest 
concentrations of HCV viremia have been reported in patients who have developed liver 





Spontaneous clearance of HCV RNA appears to be less frequent in HCV/HIV coinfection 
settings (Thomson et al., 2009). Nonetheless, spontaneous clearance of HCV RNA has been 
observed in some patients with chronic HCV/HIV coinfection who have experienced a 
significant immune reconstitution after ART initiation, especially in patients with a favorable 
IL28B CC genotype (Fialaire et al., 1999, Thomson et al., 2009, Stenkvist et al., 2014). 
 
1.10.5 Treatment of HCV in HIV coinfection 
The recommendation for the treatment of HIV coinfected patients is the same way as 
moninfected patients. Several studies have shown that effective treatment of coinfection can 
significantly reduce the risks of preexisting liver disease in HIV-positive patients (Mira et al., 
2013). This means that once virus clearance is reached, the prognosis of liver disease 
improves dramatically (even in the existence of an already developed liver cirrhosis) and once 
HCV is eradicated, further liver complications are highly unlikely for patients with low-grade 
liver fibrosis. Therefore, irrespective of the stage of liver fibrosis, treatment for HCV should 

















2 AIMS OF THE STUDY 
The advent highly potent and safe DAAs against HCV and changes in the guidelines for HIV 
treatment that recommend starting therapy as soon as possible could lead to a dramatic change 
in the epidemiology of both infections, particularly in high risk groups. Therefore, ensuring 
effective prevention and evidence-based health policy decisions in times of such paradigm 
shifts surveillance using the best possible epidemiological and molecular methods is 
mandatory. 
 
In high-income countries, the burden of HCV is high among PWIDs and increasing among 
HIV-infected MSM, who are the key populations for HCV transmission (Martin et al., 2015). 
HCV treatment for these populations could become an important prevention strategy, 
especially in the IFN-free DAA era. Hence, there is a need to explore whether the treatment 
can reduce HCV prevalence and prevent transmission among these transmission groups. 
Germany has been one of the most popular destination and host countries for asylum seekers 
in Europe during recent years with the vast majority of asylum seekers arriving between July 
2015 and February 2016 (Grote, 2018). The immigration of HCV and HIV-infected persons 
coming from countries which are traditionally characterized by a high endemicity rate can be 
a most important factor contributing to the viraemic pool in the country (Negro, 2014). 
However, a representative data on the status of HIV/HCV coinfection in the country is so far 
not available. 
 
While elimination of HCV infection in Germany seems to be feasible and cost-effective with 
the new pangenotypic interferon-free DAAs (Krauth et al., 2019), there is still a need to 
genetically characterize the currently circulating HCV strains to guide effective initial 
therapies strategies and to ensure the specificity and accuracy of viral diagnostics (AASLD, 
2018, EASL, 2018).  
 
Therefore, this study aims to conduct an up-to-date epidemiological and molecular 
surveillance of HCV coinfections among new HIV infections diagnosed between the years 
2015 and 2017 in Germany. The study also presents data on the prevalence and incidence of 
HCV, on circulating HCV genotypes/subtypes, on existing resistances in relation to the main 
transmission groups, sex groups and origin of the infected individuals. This knowledge 
enables to have an early recognition of trends, implementation of targeted and appropriate 
prevention measures or therapy optimization and the making of evidence-based health policy 




3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Equipments 











ELISA plate washer 
ELISA plate reader  
Real-Time PCR Cycler 
Heraeus B 6030 
NucliSens easyMAG 
BioDocAnalyze 
Mini Elektrophorese System 
Bleymehl-Reinraumtechnik 
 




Infinite F200 Microplate 
HydroFlex™ Microplate 
LightCycler 480 II 
Heraeus, Germany 
BioMérieux, France 






Thermo Scientific, USA  





3.1.2 Chemical reagents 
Reagent Company 
100bp DNA Ladder (LS100) 
6x Loading buffer bromophenol blue 
Tris-EDTA Buffer 
1xTAE Buffer 
Agarose Standard Rotigarose 
dNTP Mix 
GelRed 
NucliSense easyMAG Magnetic Silica (Beads) 
NucliSENS easyMAG Extraction buffer 1 
NucliSENS easyMAG Extraction buffer 2 
NucliSENS easyMAG Extraction buffer 3 




Thermo Scientific, USA 
Carl Roth, Germany 














HotstarTaq Master Mix Qiagen, Netherlands 
Monolisa™ HCV Ag-Ab ULTRA V2 Bio-Rad, USA 
Monolisa anti-HCV PLUS Version 3 Bio-Rad, USA 
recomLine HCV IgG Mikrogen, Germany 
RNasin Promega, USA 
SuperScript™ II Reverse Transcriptase (RT) Thermo Scientific, USA 
SuperScript™ III Platinum™ One-Step qRT-PCR Thermo Scientific, USA 
Agencourt® AMPure XP 
Quant-iT™ PicoGreen™ dsDNA Assay 
Beckman Coulter, USA 
Thermo Scientific, USA 
 
3.1.4 Probe 
Probe Direction Sequence       Company 
HCV-TM-5 Sense FAM 5´CCT TGT GGT ACT 
GCC TGA 3´MGB 
      Thermo Scientific, USA 
 
3.1.5 Filter Card 
Filter Card    Company 
Whatman 903 filter card     GE Healthcare Bio- 
   Sciences Corp, USA 
 
3.1.6 Device software 
Software Producer 
BioDocAnalyze Biometra, Germany 
Geneious 11.1.5 Biomatters, Newzeland 
Magellan Tecan, Switzerland 
HCV Phylogenetic Typing Tool 2.4 GenomeDetective,Belgium 
NCBI Genotyping NCBI, USA 











Extraction disposable container 
Falcon tube 










Pipette tips, epT.I.P.S. 
Pipette tips, ClipTip 
PCR tubes 
LightCycler 480 Multiwell Plate 96 
FTA-1 
200ml 
Combitips advanced®25ml, 50ml 
NucliSENSeasyMAGDisposables 
15ml, 50ml 




10, 20, 100, 200, 1000μl 




10, 20, 100, 200, 1000 μl 
20-200µl
300µl 












Thermo Scientific, USA 
Thermo Scientific, USA 
Sartorius, Germany 
Hirschmann, Germany    
Thermo Scientific, USA 
Eppendorf, Germany 
Thermo Scientitic, USA 
Sarstedt, Germany 
3.1.8 Primers for 5'UTR region 
Primer Direction Sequence Region 
235 Antisense AGT ACC ACA AGG CCT  5´UTR 
238 Sense GAG GAA CTA CTG TCT TCA CG 5´UTR 
239 Antisense TCG CAA GCA CCC TAT CAG 5´UTR 
240 Sense CGT CTA GCC ATG GCG TTA G 5´UTR 
255 Sense AGY GTT GGG TYG CGA AAG 5´UTR 
256 Antisense CAC TCG CAA GCR CCC T 5´UTR 
25 
3.1.9 Primers for NS3 region 
Primer Direction Sequence Region 
261 Sense GAT CTG GCC GTG GCT GTA GAG NS3 
262 Antisense AGC ACC TTG TAG CCC TGA GC NS3 
263 Sense GCG GTG ACA TCA TCA ACG GCT NS3 
264 Antisense GGG ACC TCA TGG TTG TCT CTA GG NS3 
265 Sense CTT GCG GTG GCA GTT GAG C NS3 
266 Antisense CCG TGG TGA TGG TCC TTA CCC NS3 
267 Sense GCT GCA TCA TCA CCA GCC TCA C NS3 
268 Antisense GGC ACC TTA GTG CTC TTG CC NS3 
280 Sense GGA GGT TGC TGG CGC CCA T NS3 
281 Antisense GCC GGG ACC TTG GTG CTC TT NS3 
283 Antisense GCG TGT AGA TGG GCC ACT TG NS3 
3.1.10 Primers for NS5A region 
Primer Direction Sequence Region 
284 Sense CAT ACT CAG CAG CCT CAC TGT NS5A 
285 Sense ACC AGT GGA TAA GCT CGG AGT G NS5A 
286 Antisense CCA TAT AAC AGC AGA GGC GGC NS5A 
289 Sense GCA CTA TGT GCC TGA GAG CG NS5A 
291 Antisense CAG TGC TCA CTT CCA TGC TCA NS5A 
292 Sense GCT GAG TTC TCT AAC TGT CAC AAG NS5A 
293 Sense ACT GTC ACA AGT CTG CTC CGG NS5A 
294 Antisense TCC ATC AGA GGC AAG CTC ATC NS5A 
295 Antisense GCT GAC CTC GAT GTT GAG AGA CC NS5A 
308 Sense ATG AAC CGG CTG ATA GCG TTC NS5A 
309 Antisense GCTCACTTCCATGCTYACCGA NS5A 
335 Sense AAA CCA TGT TGC CCC TAC CC NS5A 
336 Antisense GTC TGT CAA CAT GGA GGC CA NS5A 
337 Antisense GAG AGC CGA CCA CAA AGG AA NS5A 
362 Sense RCY ATY GCY TCC CTC ATG NS5A 
363 Sense AAG ATC ATG AGY GGY GAG A NS5A 




3.1.11 Primers for NS5B region 
Primer  Direction Sequence Region 
257 Sense GGS TTY TCN TAT GAY ACC MGV TGY TTT GA NS5B 
259 Sense GCT GYT TTG AYT CAA CNG TCA C NS5B 
270 Antisense TAY CTG GTC ATA GCY TCC GTG AAR G NS5B 
271 Sense ACC ACA TCM RST CCG TGT GG NS5B 
272 Sense TCC GTG TGG RAR GAC YTS CTR GA NS5B 
275 Antisense CTS GTC ATA GCY TCC GTG AA NS5B 
296 Sense AGG CTA TGA CCA GGT ACT CCG NS5B 
298 Antisense CTA CTC CTG CTT GCT GCA GGG NS5B 
299 Antisense TTT GCC TAC TCC TGC TTG CTG NS5B 
301 Sense CGG AGG CTA TGA CTA GGT ACT C NS5B 
302 Antisense GGA GCA GGT AGA TGC CTA CC NS5B 
303 Antisense TCA TCG GTT  GGG GAG CAG GTA NS5B 
305 Sense CTC CGT MTG GGA GGA CTT GC NS5B 
311 Sense GCGWGCCTGAGAGCCTTCAC NS5B 
 
3.1.12 Web tool 
Software Producer 
















3.2 METHODS (PART I) 
3.2.1 Longitudinal HCV panels 
For the evaluation of Murex and Monolisa Ag/Ab HCV combination assays commercially 
available HCV seroconversion panels from SeraCare Life Sciences, Inc. (Milford, MA, USA) 
were used. The panels include serial bleeds collected from two plasma donors during a period 
of HCV antibody seroconversion. The first bleeds were RNA positive and antibody negative. 
These samples had a higher HCV RNA load (>100,000 IU/ml) and can therefore be 
considered antigen positive based on data reported earlier (Soliman et al., 2015, Thong et al., 
2015), while bleeds of later time points were designated as RNA and antibody positive. The 
panels PHV917 (M) and PHV920 (M) comprised HCV subtypes 1a and 2b with bleed 
durations of 152 and 35 days, respectively. This information is also provided as part of figure 
1A and B. In addition to these seroconversion panels, panels of longitudinal HCV RNA and 
anti-HCV antibody positive serum samples were used, which contained subtypes 1b (male, 48 
years old and HIV positive; n=4), 3a (male, 49 years old and HIV positive; n=3), and 4d 
(male, 35 years old and HIV positive; n=3) each with durations since first bleed of 168, 182, 
and 176 days, respectively. These were anonymous residual samples provided by a diagnostic 
laboratory in Berlin (Medizinisches Infektiologiezentrum Berlin) along with HCV RNA and 
anti-HCV antibody test results.  
 
3.2.2 Preparation of dried serum/plasma spots 
Specimens from the panels were prepared as DS/PS, by dropping the plasma or serum (100 
µl) on Whatman 903 filter cards, air drying overnight at room temperature, packaging in a 
zip-lock bag containing desiccant packets and storing at -20°C. For use in the EIAs, 
antibodies were eluted from spots in 500 µl elution buffer (500 ml PBS, 0.05% Tween, 3% 
FCS) resulting in a 1:5 dilution.  
 
The sensitivity of Murex and Monolisa Ag/Ab HCV combination assays was first tested by 
using undiluted longitudinal HCV antibody and/or antigen-positive samples from different 
time points (HCV seroconversion panels). Since the extent of anti-HCV antibody elution and 
the performance of the two assays for different antibody concentrations are not known, the 
DS/PS eluates (1:5 dilution) were further diluted in different amounts of an elution buffer 
resulting in dilutions of 1:10, 1:15, 1:50, and 1:100. The DS/PS dilutions were then compared 





To further analyze the performance of both combination assays, clinical DSS eluates, which 
represent anonymous residual serum spots of new HIV diagnoses (for details see (Hauser et 
al., 2017) were used for screening of potential HCV coinfections and calculation of the 
percentage of correct positive test results. For lack of a “gold standard” commercial assay, 
ELISA-reactive samples were confirmed by an in-house quantitative RT-qPCR assay, which 
is optimized for quantifying HCV RNA in DSS (Wang et al., 2019). HCV RNA negative 
ELISA reactive samples (presumed resolved infections) were analyzed by Western blot to 
confirm seroconversion.  
 
3.2.3 Assays for the combined Ag/Ab detection 
3.2.3.1 Murex Ag/Ab combination assay 
The wells of the Murex Ag/Ab HCV combination assay are coated with anti–core monoclonal 
antibody for the detection of HCV antigen and recombinant antigen, peptides representing the 
immunodominant regions of the NS3 protein and core viral antigens for the detection of HCV 
antibodies. The assay was performed as recommended by the manufacturer. Briefly, 50 µl of 
sample diluents and the same volume of specimens or controls were added to each of the 
microplate wells. The plates were then incubated at 37 0C for 1 h followed by five washing 
steps, after which 120 µl of conjugate (containing HCV antigens and a monoclonal antibody 
conjugated to horseradish peroxidase) was added to all wells. The microplates were then 
incubated for 1 h at room temperature. The microplate was washed again, 80 µl of substrate 
was added to each of the wells, and incubated for 30 minutes at 37 0C. Lastly, stop solution 
was added and the plates were read at 450/620 nm using an Infinite 200 PRO Microplate 
reader (Tecan). The cut-off value was determined by adding 0.2 to the mean OD of the 
negative control. 
 
3.2.3.2 Monolisa Ag/Ab ULTRA assay 
The test process for the Monolisa HCV Ag/Ab ULTRA was also performed following the 
instructions of the manufacturer. The wells of the microplates are coated with monoclonal 
antibodies specific for HCV capsid, NS3 and NS4 purified recombinant proteins, and a 
peptide from the capsid of HCV. For the assay 50 μl of sample and controls were incubated at 
37 0C for 90 minutes, with 100 μl of conjugate 1 (biotinylated anti-HCV capsid monoclonal 
antibody). After a cycle of washing steps, 100 μl of conjugate 2 (peroxidase-labeled 
antibodies to human immunoglobulin G and streptavidin-peroxidase) was added to each well 




complex was revealed by the addition of substrate. The reaction was stopped after 30 minutes 
of incubation at room temperature by adding a stop solution. The OD was read at 450/620 nm 
using the same microplate reader. The cut-off value was determined as the mean of positive 
control OD divided by 4.  
 
3.2.4 Data analysis and interpretation 
Data entry and analyses were performed using GraphPad Prism 7 (GraphPad Software). All 
samples were tested in duplicate and the test of samples in both assays was performed 
simultaneously. A sample was considered as positive when the mean difference (± standard 




























3.3 METHODS (PART II) 
3.3.1 Study participants 
For the evaluation of an in-house HCV recency assay, the DS/PS specimens were prepared 
from primary or follow-up samples collected from: (i) the national multicenter long-term 
observational German HIV-1 Seroconverter (SC) Study at the Robert Koch Institute 
(Machnowska et al., 2017, Machnowska et al., 2019) (ii) a Commercial HCV seroconversion 
panel (PHV920(M); SeraCare, MA, USA) (iii) a panel provided by the Institute of Virology, 
University Duisburg-Essen, Essen, Germany (iv) a panel provided by the Medizinisches 
Infektiologiezentrum Berlin, Berlin, Germany. Participants of the German HIV-1 
Seroconverter (SC) Cohort gave signed informed consent. The study was approved in 2005 
and reapproved in 2013 by the Ethics Committee of the Charité, University Medicine Berlin 
(EA2/105/05). For seroconverters from the SC Cohort and from the panel obtained from the 
MedizinischesInfektiologiezentrum Berlin, the date of the last negative test result was 
available and the date of infection was calculated as the arithmetic mean from the last 
negative and a first positive documented HCV-antibody test result. Only patients with a 
maximal time interval of 90 days between the last negative and the first positive HCV-
antibody test results were included in the study to keep the infection date as precise as 
possible. Additional information regarding HIV status, sex and age of the HCV 
seroconversion panels were provided by the diagnostic laboratories at the time of sample 
collection. HCV genotype was determined as described by (Wang et al., 2019). 
 
3.3.2 Evaluation panel 
To evaluate the avidity assay we used three evaluation panels: panel 1 consisted of primary 
and at least one follow-up samples to analyze the temporal changes of AIs over time in 
genotype 1 (n=170) and non-genotype 1 infections (n=48; total=218). One aim of this analysis 
was to find the optimal cut-off value for the avidity assay, i.e. the cut-off value that optimizes 
the accuracy of the assay. For an AI below that cut-off value, the assay gives a positive result 
and the infection is classified as recent. Therefore, a sub-panel (1a) of longitudinal DS/PS 
obtained from individuals with primary and at least two follow-up samples (18 individuals; 2-
6 specimens per individual; total=66) was used to estimate the probability that a sample is 
classified as recent as a function of the known duration of infection by Mixed-effects logistic 
regression for an optimal AI cut-off. The fixed part of the model was described by 
(Brookmeyer et al., 2013) and the random effects accounted for multiple samples contributed 




the cubic terms in the regression model. We calculated the `Mean Duration of Recent 
Infection´ (MDRI) by numerical integration assuming that this probability is zero for 
durations longer than 2 years. Another sub-panel (1b) constituting a follow up of acute cases 
(<26 weeks; `recent infection sample set’) was used to calculate the false long-term infection 
rate (FLTR) (identical to 100 minus sensitivity). 
 
Panel 2 comprising DS/PS samples obtained from 132 individuals with chronic HCV 
infection who were anti-HCV IgG positive and HCV RNA positive for more than 2 years 
(>104 weeks; ‘long-term infection sample set’) was used to calculate the false recent rate 
(FRR) (identical to 100 minus specificity). Both FLTR and FRR were calculated for all 
genotypes and separately for genotype 1 and non-genotype 1 infections, for AI cut-off values 
from 10% to 45% with an increment of 5%. 
 
Panel 3 consisting of 32 samples with a resolved infection and a minimum follow-up of 180 
days after clearing the infection (range: 259-2,863 days) was also used to calculate the FRR. 
 
3.3.3 Dried serum/plasma spots 
The assay was established and evaluated for the use of DS/PS. For preparation of DS/PS 
plasma or serum samples (100 µl) were dropped on Whatman 903 filter cards (GE Healthcare 
Bio-Sciences Corp), air dried overnight at room temperature packaged in a zip-lock bag 
containing desiccant packets and stored at -20°C immediately for approximately one month 
before tested. For application, antibodies were eluted from spots in 500 µl elution buffer (500 
µl PBS, 0.05% Tween, 3% FCS) resulting in a 1:5 dilution for the avidity assay. 
 
3.3.4 Modified BioRad avidity assay 
The HCV immunoglobulin G (IgG) antibody avidity assay was developed by using a 
Monolisa Anti-HCV PLUS Version 3 ELISA kit (BioRad) and a modified protocol from Patel 
and coworkers (Patel et al., 2016). Patel and colleagues utilized in their study the Ortho HCV 
Version 3.0 ELISA (Ortho Clinical Diagnostics) test system with 10 μl of specimen in 200 μl 
of sample diluent and performed an initial sample incubation of 30 minutes at 4°C. In 
contrast, in this study DS/PS eluates were applied in duplicate on antigen-coated wells (50 μl 
of specimen in 100 μl of sample diluent) and incubated overnight at 37°C. We optimized the 
duration of sample incubation and temperature in a preliminary test to increase the amount of 




buffer treated wells, defined to be >1 and <4) in order to optimize the differentiation between 
recent and long-term infections. In addition, one recent and one long-standing sample with 
known duration of infection each (<3 months and >2 years of infection, respectively) were 
used as internal test controls. In agreement with Patel and colleagues, for the dissociation step 
the first well of each sample was manually treated with 200 μl of 0.025M diethylamine (DEA; 
diluted with wash buffer) to dissociate antigen antibody complexes and the second well of the 
same sample was treated with wash buffer as a control. The plate was then incubated for 30 
minutes at 37°C, followed by washing with wash buffer (300 μl) 5 times. The remainder of 
the test (beginning with the addition of conjugate) was performed according to the 
manufacturer’s instructions. Samples treated with wash buffer with an OD <1.0 were 



























3.4 METHODS (PART III) 
3.4.1 Clinical samples 
According to the “Protection against Infection Act” (IfSG; §7) of 2001, newly diagnosed HIV 
infections are anonymously reported to the German public health institute (Robert Koch 
Institute, RKI). For surveillance programs a network of approximately eighty diagnostic 
laboratories was established that send along with the report form, residual serum from newly 
diagnosed HIV cases spotted onto a filter card (Whatman 903 filter cards, GE Healthcare Bio-
Sciences Corp) as DSS. According to §13 of IfSG, the RKI is authorized to receive blood 
residuals from diagnostics for surveillance purposes. By this sampling strategy, specimens 
from approximately 60% of all reported newly diagnosed HIV infections are send to the RKI 
laboratory. HIV notifications and DSS samples were linked by using the number on the HIV 
notification form. Data on age, gender, mode of transmission, region of origin and assumed 
region of infection were used from the associated HIV notification form. Exclusion criteria 
were unknown information on gender or age, age below18 years, or DS/DP samples from 
double-notified HIV cases. Ethical approval for the nationwide cross-sectional study was 
given by the ethics board at the Charité, University Medicine, Berlin, as well as approval from 
the data protection office of Germany according to the Federal Data Protection Act. The DSS 
samples used were residuals from routine HIV diagnostic processing; therefore, no patient 
informed consent was given (Hauser et al., 2018). 
 
3.4.2 Workflow of the project 
DSS from newly reported HIV infections with a date of diagnosis between the diagnoses 
years 2015 and 2017 were analyzed for the presence of anti-HCV antibodies and/or antigen 
by means of ELISA (Monolisa HCV Ag-Ab ULTRA V2, Bio-Rad). ELISA-reactive (ELISA-
positive) samples were further characterized into active infections (HCV seropositive + HCV 
RNA-positive) or resolved infections (HCV seropositive + HCV RNA-negative) by an in 
house real-time RT-PCR (qPCR) targeting the 5’UTR of the HCV genome. Furthermore, 
qPCR positive samples were classified into recently acquired and long-term HIV-infections 
using the already established an in-house recency assay. On the other hand, qPCR-negative 
samples were further analyzed by an Immunoassay (MIKROGEN, 2019) to identify false 
positive samples in the initial screening ELISA and to define the true proportion of HCV 
positive samples (HCV seropositive and/or HCV-RNA positive). Genotyping (based on 









Fig. 7: Workflow of the project. 
 
3.4.3 The Pre-DAA study 
Analysis of HCV coinfection among newly diagnosed HIV cases in prior to the introduction 
of HCV-specific antiviral drugs (pre-DAA) in Germany was performed by Johanna Riege 
(Bachelor thesis) (Riege et al., 2019). The aim of this bachelor thesis was to gain an overview 
of HCV coinfections in HIV new diagnosis before the introduction of DAA therapy in the 
diagnoses years 2009-2011. The data from the pre-DAA study was taken for comparison with 
the current study (2015-2017) to assess the potential impact of DAA therapy in terms of 
disease outcomes and HCV subtype distribution in Germany. 
 
3.4.4 Laboratory testing 
3.4.4.1 ELISA 
DSS were screened using a commercially available antibody/antigen ELISA (Monolisa Ag-




3.4.4.2 Nucleic acid (RNA) extraction 
RNA was semi-automatically extracted using the NucliSENS® easyMAG platform 
(BioMérieux) according to the manufacturer`s instructions. Accordingly, 2 DSS (each with 
100 μl serum) were placed in a 2 ml Eppendorf tubes and mixed with 1.8 ml Lysis buffer. The 
samples were then shaken for one hour at about 300 rpm and room temperature. Thereafter, 
1.5 ml of the lysed eluate was withdrawn and transferred to a disposable reaction vessel. After 
adding 50 μl of magnetic silica solution, the samples were mixed with an automatic pipette 
and positioned in the extractor. The device was then set and started as described in the 
instruction (protocol: Generic 2.0.1, quantity: 0.4ml, eluate: 60μl, sample type: serum). RNA 
was extracted by automated magnetic separation and finally eluted in 60 μl of elution buffer 
(Fig. 8). The Extracted RNA was aliquoted in portions of 10 μl and immediately stored at -
80°C until further use. 
 
Fig. 8: Principle of nucleic acid extraction with the Biomerieux NucliSense® easyMAG® 
(BioMérieux, 2019). 
A) During incubation of the lysed samples, all the target nucleic acid is captured by magnetic silica 
particles. B) The NucliSens® easyMAG® magnetic device attracts all the magnetic silica, enabling 
the system to purify the nucleic acids through several washing steps. C) The heating step releases the 
nucleic acids from the silica. D) At the final step, the magnetic silica particles are separated from the 
eluate by the magnetic device.  
 
3.4.4.3 RT-qPCR 
The 5’UTR is a highly conserved region of the HCV genome and is targeted by most 
diagnostic assays for HCV RNA. Based on the consensus sequence of this region, an in-house 
quantitative real-time PCR (qPCR) was used for viral quantification and for distinguishing 
active and resolved HCV infections. To prepare the Master Mix, the PCR kit SuperScript® III 
Platinum® One-Step qRT-PCR Kit (ThermoFisher GmbH) was used. As described in table 2, 




plate. Standards (plasma samples of HCV genotype 1a in concentration 10E+01-10E+06 
international units (IU)/ml) and negative controls (HCV-negative plasma) were also analyzed 
in each run. 
 
Table 2: Master Mix composition for the RT-qPCR. 
RT-qPCR   Master Mix 

































+Template (RNA)   4 
 
After a short centrifugation, the plate was placed in the Lightcycler 480 II (Roche) and the 
samples were amplified according to the program in table 3. Each sample was analyzed in 
duplicate and the mean concentration per samples was extrapolated using the standard curve.  
 
Table 3: Cycler program for the RT-qPCR. 




Annealing and Elongation 
50°C 
95°C 
95°C (ΔR 3°C/s) 










3.4.4.4 cDNA synthesis 
In order to further characterize the viral subtypes and drug resistance profiling of the samples 
identified as active infection (RNA positive) by the qPCR, the extracted RNA was transcribed 
into cDNA and subsequently amplified in a nested PCR for further use in a genotyping and 




Master Mix was prepared as described in table 4. Then 10μl of the sample and 10μl of the mix 
were pipetted together and mixed by up and down pipetting. 
 
Table 4: Master Mix composition for cDNA synthesis. 
cDNA   Master Mix 
Reagents Stock concentration Concentration final µl/sample 
RT-Puffer 
dNTP 


























The cDNA synthesis was then carried out according to the following protocol in table 5. After 
synthesis, the cDNA was stored at -25° C until use. 
 
Table 5: Cycler program for cDNA synthesis. 










3.4.4.5 Western blot  
The recomLine HCV IgG is a line immunoassay (Western blot) that serves to detect 
antibodies present in a sample for qualitative detection of antibodies against individual 
antigens of HCV and is used as confirmatory test if a previous antibody screening test 
(Monolisa Ag-Ab Ultra V2, BioRad) was reactive. The test principle allows for separate 
lining up of the individual antigens and thus, unlike ELISA, for the identification of specific 
antibodies against the individual HCV antigens (Core 1, Core 2, Helicase, NS3, NS4, and 
NS5). In the first step, the test strip was incubated with DSS eluate (20μl sample at 2ml wash 
buffer per strip) in a dish for 3 hours with gentle shaking. In this case, the existing HCV 
antibodies from the samples bind to the antigens fixed on the test strips. The unbound 




of peroxidase conjugated anti-human antibodies (IgG specific) were added and incubated for 
45 minutes while shaking gently. The unbound antibodies were removed by washing 3 times 
with washing buffer. Finally, 1.5ml of a ready-to-use substrate solution was added and 
incubated for 8 minutes with gentle shaking. The reaction was then stopped by washing the 
strips at least three times with deionisied water. If an antigen-antibody reaction has taken 
place, a dark band appears on the strip at the corresponding point. Analysis of the bands on 
the test strips was done on the following day by using the instructions found in the kit insert 
(MIKROGEN, 2019). 
 
3.4.4.6 Nested PCR for genotyping and subtyping 
For the genotyping and subtyping of HCV, both sequences from the 5'UTR region and the 
NS5B region of the HCV genome can be used. However, since the 5'UTR range is highly 
conserved, it is difficult to distinguish between individual subtypes. In particular, subtypes 1a 
and 1b are difficult to differentiate because they differ only in a single base at position -99 in 
the 5'UTR (Chen and Weck, 2002). Due to its variable nucleotide sequence and based on the 
consensus criteria used by Smith et al (Smith et al., 2014), the NS5B region has become 
particularly well suited region for the identification of both HCV subtypes and DAA 
mutations.  
 
However, due to the use of DSS, RNA degradation needs to be considered for the choice of an 
appropriate PCR-assay, especially the size of the amplicon should not exceed 900bp 
(experience from our laboratory). For this region, the resistance associated positions are 
spread over a length of 1200 bp and; therefore, the use of 2 primers for amplifying regions of 
DAA resistance is a problem. Hence, two sets of primers (“long” genotyping part I and NS5B 
part II) were designed and established (Fig. 9). The “short” genotyping is used as a backup 









In case that both PCR-assays were negative a two-step nested-RT-PCR with primers lying in 
the 5’UTR was used, in order to obtain a subtype for as many samples as possible. 
 
In the case of long nested PCR, the external primers 271 (sense), 275 (antisense) and 305 
(sense) were used to amplify a 685bp PCR product (Table 18). For this, 11.5 μl of the 
prepared Master Mix (Table 6) was mixed with 1 μl of the cDNA template and amplified 
according to the program below (Table 7). 
 
Table 6: Master Mix composition for the first round NS5B “long” nested PCR. 
1.PCR   Master Mix 



































+Template (cDNA)   1 
 
Table 7: PCR cycler program for the first round NS5B “long” nested PCR. 











60°C (ΔT -1°C, ΔR 1°C/s) 
72°C 
94°C 


























The second round long-nested PCR was carried out with primers 272 (sense) and 275 
(antisense) resulting a final PCR-product of 674bp (Table 18). For this, 0.75μl was taken from 
the final PCR product and mixed with a second Master Mix (Table 8) and re-amplified as per 
the program in table 9. 
 
Table 8: Master Mix composition for the second round NS5B “long” nested PCR. 
2.PCR   Master Mix 



















+Template (1.PCR)   0.75 
 
Table 9: PCR cycler program for the second round NS5B “long” nested PCR. 

























For the first round short-nested PCR, the primers 257 (sense) and 270 (antisense) were used to 
produce a PCR product of 392bp (Table 18).The primer pairs were mixed with 11.5μl of the 
prepared Master Mix (Table 10) and mixed with 1μl of the cDNA template. The amplification 










Table 10: Master Mix composition for the first round NS5B “short” nested PCR. 
1.PCR   Master Mix 





























+Template (cDNA)   1 
 
Table 11: PCR cycler program for the first round NS5B “short” nested PCR. 









  95°C 
94°C 
60°C (ΔT -1°C, ΔR 1°C/s) 
72°C 
94°C 























After the first round short nested PCR, 0.75 μl of the PCR product was transferred to 11.75 μl 
of a new Master Mix (Table 12) which contains primers 257 (sense), 259 (sense) and 270 











Table 12: Master Mix composition for the second round NS5B “short” nested PCR. 
1.PCR   Master Mix 





















+Template (cDNA)   0.75 
 
Table 13: PCR cycler program for the second round NS5B “short” nested PCR. 






  95°C 
94°C 

















For the first round 5'UTR nested PCR, primers 238 (sense) and 239 (antisense) were used to 
produce a product of 262bp (Table 18). The primer pairs were mixed with 11.5μl of the 
prepared Master Mix (Table 14) which was then mixed with 1μl of the cDNA template. The 
final mix was amplified according to the program below (Table 15). 
 
Table 14: Master Mix composition for the first round 5’UTR nested PCR. 
1.PCR   Master Mix 





















∑   11.5 




Table 15: PCR cycler program for the first round 5’UTR nested PCR. 

























For the second round 5'UTR nested PCR, primers 235 (antisense) and 240 (sense) were used 
resulting in a product length of 215bp (Table 18). For this, 0.75μL of the first PCR product 
was mixed with 11.75 μl of the prepared Master Mix (Table 16) and re-amplified according to 
the program in table 17. 
 
Table 16: Master Mix composition for the second round 5’UTR nested PCR. 
2.PCR   Master Mix 




















+Template (1.PCR)   0.75 
 
Table 17: PCR cycler program for the second round 5’UTR nested PCR. 




























Table 18: Details of the primers used for qPCR, NS5B (“long”), NS5B (“short”), and 
5UTR PCRs. 







AGY GTT GGG TYG CGA AAG 
CAC TCG CAA GCR CCC T 









ACC ACA TCM RST CCG TGT GG 
TCC GTG TGG RAR GAC YTS CTR GA 
CTS GTC ATA GCY TCC GTG AA 
CTC CGT MTG GGA GGA CTT GC 
Outer PCR:  
685 











GGS TTY TCN TAT GAY ACC MGV TGY TTT 
GA 
GCT GYT TTG AYT CAA CNG TCA C 













AGT ACC ACA AGG CCT TTC G 
GAG GAA CTA CTG TCT TCA CG 
TCG CAA GCA CCC TAT CAG 









F=forward; R=reverse; *Position according to HCV reference genome HCV-1a (AF009606). 
 
3.4.4.7 Sanger-sequencing and evaluation 
Samples which were positive in one of the three (NS5B-“long”, NS5B-“short” or 5'UTR) 
nested-RT-PCR assays were considered for genotyping/subtyping and were further sequenced 
using the BigDye Terminator v3.1 cycle Sequencing Kit. First, 5µl of PCR-product were first 
purified using 2μl of ExoSAP-IT (cycle program: 15 mins at 37°C., then 15 mins at 80°C). 
Then, 9μL of the prepared Master Mix was mixed with 1μL of the purified PCR products 
(Table 19) and amplified according to the cycler program shown in table 20. As for 
sequencing primers, the respective inner primers of the nested PCR were used. Hence, for 
PCR-products positive in the NS5B-“long” nested-PCR, primers HCV-259-F, HCV-272-F 
and HCV-275-R were used. For PCR-product generated by NS5B-“short” nested-PCR, 




product obtained by 5’UTR-nested-PCR, primers HCV-235-R and HCV-240-F were used 
(Table 18). The sequencing took place in the in-house sequencing laboratory. 
 














Table 20: PCR cycler program for Sanger sequencing. 





















Due to the fact that HCV is present as so-called quasispecies, there is a population of closely 
related but different viruses. Thus, different bases can occur at one and the same position in 
the genome (ambiguities). Therefore, manual correction of the raw sequence data was done by 
using Geneious® 11.1.5 (Biomatters), aligned to a reference sequence (HCV-1a_AF009606), 
and trimmed by their quality. The sequences were then checked for the presence of 
ambiguous positions using the IUPAC-IUB codes and the consensus-sequences were saved as 
fasta-file. The subtypes were determined using geno2pheno, a web-tool offering detailed sub-
genotyping of HCV as well as analysis of DAA-susceptibility for each drug target (Kalaghatgi 
et al., 2016). For samples sequenced by the 5'-UTR nested PCR, the HCV phylogenetic 
typing tool 2.4 (GenomeDetective) and the NCBI genotyping tool (Rozanov et al., 2004), 
both available as a web tool, were used to determine the subtype. If different subtypes were 
identified for a sequence in the two web tools, a clear classification of the subtype was not 
possible and the genotype was only used for data analysis. Due to a lack of sequence 




3.4.4.8 Nested PCR for drug resistance mutations 
Due to the degradation of RNA on DSS and the high divergence of HCV, the design of 
genotype-and even subtype specific primers was necessary to cover resistance associated 
positions in the NS5B, NS3, and NS5A regions of the genome. For this reason, an alignment 
with 204 sequences of all HCV subtypes (available from the Los Alamos HCV database) was 
generated. The drug resistance mutations were identified based on Pawlotsky et al 
(Pawlotsky, 2016) with a list of amino acid substitutions reported to reduce susceptibility of 
different HCV genotypes or subtypes to DAAs. According to this, primers were designed for 
NS3, NS5A, and NS5B regions of genotype 1 (subtypes 1a and 1b) and NS5A region of 
genotype 2 (all subtypes), genotype 3 (subtype 3a), and genotype 4 (all subtypes) (Fig. 10). 
However, since genotype 5, 6 and 7 are mostly prevalent in Africa and Asia; primers were not 




Fig. 10: Workflow for detection of resistance mutations against DAAs in different HCV 
subtypes.  
 
Tables 21 and 22 show the different primer combinations used to cover resistance associated 
mutations in the NS3, NS5A and NS5B regions of different subtypes. The alternative PCRs 
were used as a backup PCR for amplifying samples which were negative in the standard 
PCRs. For all HCV subtypes of the first round nested PCR, 0.5μl of the primer pairs (400nM) 
























Mix to prepare a Master Mix volume of 11.5μl, which was finally mixed 1μl of the cDNA 
template. For the second round nested PCR, 0.25μl of the primer pairs (200nM) were mixed 
with 5μl of water and 6.25μl of Hot Start Master Mix with a final Master Mix volume of 
11.75μl. The Master Mix was then mixed with 1μl of the product from the first round PCR. 
 
For the first round standard nested PCR, an initial denaturation step of 15min at 95oC was 
used in all programs, followed by a second denaturation of 10sec at 94oC repeated for 10 
cycles. The annealing step was performed for 45sec for NS3 region of subtype 1a at 60°C (ΔT 
-1°C, ΔR 1°C/s)], subtype 1a (alternative) and subtype 1b at 50°C (ΔT +0.4°C, ΔR 1°C/s), 
NS5A region of subtypes 1a, 1b, and 3a and for NS5B region of subtypes 1a and 1b at 50°C 
(ΔT +0.5°C, ΔR 1°C/s) and then an elongation step of 15sec at 72°C. Both steps were 
repeated for 10 cycle and the subsequent 30 cycles were performed for 10sec at 94°C, 45sec 
at 55°C and 45sec at 72°C. Finally, an elongation period of 2min at 72°C was performed in 
Biometra Trio thermocycler (Biometra GmbH). 
 
The second round nested PCR was performed for all programs using an initial denaturation 
step of 15 min at 95°C and a second denaturation of 15 sec at 94°C. The annealing step was 
performed for 45 sec for NS3 region of subtype 1a at 54°C (ΔR 1°C/s), subtype 1a 
(alternative) at 52°C (ΔR 1°C/s) and subtype 1b at 50°C (ΔT +0.5°C, ΔR 1°C/s), NS5A 
region of subtype 1a at 54°C (ΔT +0.5°C, ΔR 1°C/s), subtypes 1a, 1b and 3a at 50°C (ΔT 
+0.5°C, ΔR 1°C/s) and for NS5B region of subtypes 1a and 1b at 50°C (ΔT +0.5°C, ΔR 
1°C/s) and then an elongation step of 45 sec at 72oC. After repeating both steps for 10 cycles, 
a second stage of 25 cycles was followed for 10sec at 94°C, 45sec at 55°C (ΔR 1°C/s) and 
45sec at 72°C (ΔR 1°C/s). An elongation step of 2 min at 72oC was performed in all programs 













Table 21: Primer combinations used for PCRs in the NS3, NS5A and NS5B regions of 

















NS3 1a 261 + 262 263 + 281 263 + 264 280 + 281 
1b 265 + 266 - 265 + 283 267 + 268 
NS5A 1a 284 + 286 - 285 + 286 - 
1b 308 + 309 - 289 + 291 - 
3a 292 + 294  292 + 293 + 294 293 + 295 292 + 293 + 295 
2a/b 335 + 336 - 335 + 337 - 
4a/d 362 + 364 - 363 + 364 - 
NS5B 1a 297 + 311+ 298 - 296 + 299 - 























Table 22: Details of the primers used for PCRs in the NS3, NS5A and NS5B regions of 
different HCV subtypes. 
Genome 
region/Subtype 
Sequence 5‘-3 Lengthouter/inner 
(bp) 
Position 
NS3-1a 261FGAT CTG GCC GTG GCT GTA GAG 
262R AGC ACC TTG TAG CCC TGA GC 
263F GCG GTG ACA TCA TCA ACG GCT 
264RGGG ACC TCA TGG TTG TCT CTA GG 
Alternative PCR 
263F GCG GTG ACA TCA TCA ACG GCT 
280F GGA GGT TGC TGG CGC CCA T 













NS3-1b 265FCTT GCG GTG GCA GTT GAG C 
266RCCG TGG TGA TGG TCC TTA CCC 
265FCTT GCG GTG GCA GTT GAG C 
283R GCG TGT AGA TGG GCC ACT TG 
Alternative PCR 
265FCTT GCG GTG GCA GTT GAG C 
266RCCG TGG TGA TGG TCC TTA CCC 
267F GCT GCA TCA TCA CCA GCC TCA C 













NS5A-1a 284FCAT ACT CAG CAG CCT CAC TGT 
286R CCA TAT AAC AGC AGA GGC GGC 
285F ACC AGT GGA TAA GCT CGG AGT G 
286RCCA TAT AAC AGC AGA GGC GGC 
720/676 *1 6179-6899 
NS5A-1b 308F ATG AAC CGG CTG ATA GCG TTC 
309R GCTCACTTCCATGCTYACCGA 
289FGCA CTA TGT GCC TGA GAG CG 
291R CAG TGC TCA CTT CCA TGC TCA 
785/731 *2 6075-6859 
NS5A-3a 292FGCT GAG TTC TCT AAC TGT CAC AAG 
294R TCC ATC AGA GGC AAG CTC ATC 
293FACT GTC ACA AGT CTG CTC CGG 
295RGCT GAC CTC GAT GTT GAG AGA CC 
Alternative PCR 
292FGCT GAG TTC TCT AAC TGT CAC AAG 
293FACT GTC ACA AGT CTG CTC CGG 
294R TCC ATC AGA GGC AAG CTC ATC 
295RGCT GAC CTC GAT GTT GAG AGA CC 
765/679 *3 6198- 6962 
NS5A-2a/b 335FAAA CCA TGT TGC CCC TAC CC 
336RGTC TGT CAA CAT GGA GGC CA 
335F AAA CCA TGT TGC CCC TAC CC 
337RGAG AGC CGA CCA CAA AGG AA 
754/698 *4 6131-6885 
NS5A-4a/d 362FRCY ATY GCY TCC CTC ATG 
364RGRC AGG GRC ACT TGA BRT T 
363FAAG ATC ATG AGY GGY GAG A 
364RGRC AGG GRC ACT TGA BRT T 
988/745 *5 5635-6622 
NS5B-1a 297FGCG AGC CTG AGA GCC TTC AC 
311F GCGWGCCTGAGAGCCTTCAC 
298R CTA CTC CTG CTT GCT GCA GGG 
296F AGG CTA TGA CCA GGT ACT CCG 
299R TTT GCC TAC TCC TGC TTG CTG 
747/720 *1  8601- 9348 
NS5B-1b 301FCGG AGG CTA TGA CTA GGT ACT C 
303RTCA TCG GTT  GGG GAG CAG GTA 
301FCGG AGG CTA TGA CTA GGT ACT C 
302RGGA GCA GGT AGA TGC CTA CC 
758/747 *28605-9362 




3.4.4.9 Agarose gel electrophoresis 
The success of all PCRs was checked by applying the PCR products on an agarose gel. This 
has served as an initial assessment of whether the PCR results and a further sequencing of the 
samples would be possible. A DNA size marker (100bp DNA Ladder (LS100); Invitrogen) 
was used to determine the size of the PCR product and thus the result of the PCR can be 
evaluated as positive or negative by a visible band at the correct level. To prepare the gel, 
1.5% agarose powder (Carl Roth) was dissolved in 1X Tris-Acetate EDTA (TAE) buffer 
(Thermo Scientific). Then, the solution was heated in a microwave oven for 2–3 minutes, 
mixed with 1μl/10ml GelRed (Biotium) and poured into a gel tray with the well comb in 
place. After allowing it to cool at a room temperature for 10-15 mins, the gel was then put 
into an electrophoresis chamber and filled with 1xTAE buffer until the gel is covered. Then, 
2.5µl of each PCR product and the DNA marker (100bp; Invitrogen.) were mixed with 6X 
DNA loading dye (bromophenol blue; NEB) and loaded into each well. The gel 
electrophoresis was performed for 50 minutes at 100 volts/cm. Visualization of the DNA 
bands was done by the BioDocAnalyze (Biometra GmbH).   
 
3.4.4.10 Purification of PCR products 
For subsequent sequencing, it is necessary to free PCR products from nucleotides, salts, and 
enzymes. For this purpose, the PCR products were purified using the protocol of the 
Agencourt® AMPure XP Kit (Beckman Coulter). The technology is based on solid-phase 
paramagnetic beads for high-throughput purification of PCR amplicons. First, the 
paramagnetic beads are added to the PCR products (ratio 1: 1.8); these then bind the DNA 
fragments. With the aid of a magnet, the magnetic particles can be separated with the DNA 
from the remaining components of the preceding PCR. In the two purification steps, the 
particles are also separated from the ethanol by means of magnets. After elution of the 
purified PCR products, they can be transferred to a new plate. The described steps of this 
purification are again shown as an overview in Fig. 11. For the purification, in each case, 20μl 
of PCR product and 36μl of the magnetic particle reagent were used. The washing steps were 
carried out in accordance with the Agencourt protocol with 80% ethanol instead of 70%, as a 
better yield had been shown in a series of previous tests in the working group. Finally, the 








Fig. 11: Scheme of purification of PCR products using Agencourt® AMPure XP 
(BeckmanCoulter, 2019). 
 
3.4.4.11 Quantification of the purified PCR products 
The purified PCR products were quantified photometrically according to the protocol of the 
Quant-iT™ PicoGreen® kit (Thermoscientific, 2019). First, 100 μl of sample were diluted 
with Tris-EDTA (TE) buffer (Promega) in a ratio of 1:50 in a black 96-well microtiter plate, 
with a UV-impermeable film bottom. In addition, a standard series was included in each 
measurement, which was diluted from a lambda DNA standard (100μg/ml). For 
quantification, the fluorescent dye PicoGreen was used. This first had to be diluted 1:200 with 
TE buffer. Subsequently, the samples as well as the standard series and the blank were mixed 
with 100μl PicoGreen. The fluorescence intensity was measured at 520 nm with a reference 
wavelength of 480 nm on the Tecan InfiniteF200 reader (Tecan). 
 
3.4.4.12 Next generation sequencing (NGS) 
For the sequencing of regions associated with  resistance associated mutations (NS3, NS5A, 
and NS5B), the Next Generation Sequencing method was performed on the Illumina MiSeq® 
(Illumina, 2019) in accordance with the instructions of the manufacturer. As described in 
Machnowska et al (Machnowska et al., 2017), the NGS data were processed through an in-
house bioinformatics pipeline making use of the tools Trimmomatic (version 0.36), FLASH 
(version 1.2.11), and BWA (version 0.7.15), all wrapped in a Python script. After adapter-
clipping, trimming and merging, several iterations of mapping against a personalized 
constructed reference sequence (which is based on genotypes 1, 2, 3 and 4) were performed. 
Potential insertions and deletions were considered during the mapping cycles. The final output 
was subject to further Python scripts, which enabled codon-based variant detection and 
generation of a consensus sequence containing ambiguities according to an adjustable 
threshold. For a direct comparison with Sanger sequencing, an NGS limit of 20% was used. 




mutation analysis. After a manual correction of the raw sequence data on Geneious® 11.1.5 
(Biomatters), the drug resistance mutations were then determined using the geno2pheno 
software (Kalaghatgi et al., 2016). 
 
3.4.4.13 Statistical analysis 
Descriptive statistical analysis was performed with calculation of means and standard 
deviation (SD), frequencies and confidence intervals (CI) of 95%. Categorical variables were 
compared using the Chi-squared test, fisher’s exact test and odds ratio when was appropriate. 
P-values were 2-tailed and statistical significance was defined as p<0.05. Statistical analyses 
were performed using GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego, CA) and 






















4.1 RESULTS (PART I) 
HCV Ag/Ab assays offer the benefit of reducing the window period compared to assays that 
detect only HCV-Ab. In this study the performance of the Murex Ag/Ab (Murex, Abbott) and 
Monolisa Ag/Ab Ultra (Monolisa, Bio-Rad) ELISAs was compared for the use of filter dried 
serum/plasma spots (DS/PS) with a focus on the sensitivity and the percentage of correct 
positive test results. 
 
The sensitivity of the two assays was first analyzed using the commercially available 
seroconverter panels. As depicted in Fig. 12A, for HCV subtype 1a plasma reference samples, 
the Murex became reactive at first bleed (day 0; HCV RNA positive and antibody negative), 
while the Monolisa was reactive 13 days after the first bleed (HCV RNA positive and 
antibody positive). For DPS eluates, the Murex was only reactive for the 1:5 dilutions at days 
7, 13, 16, and 26. However, the Murex failed to be reactive for any of the higher DPS eluate 
dilutions (1:10-1:100). In contrast, the Monolisa was reactive for antibody positive DPS 
dilutions of 1:5-1:15 for the bleeds between days 16-35. It was also reactive for the higher 
dilutions (1:50 and 1:100) at later time points (between days 28-35). 
 
For HCV subtype 2b plasma reference samples, the Murex became reactive 20 days after the 
first bleed (HCV RNA positive and antibody negative) while the Monolisa was reactive 85 
days after the first bleed (HCV RNA negative and antibody positive). For dilutions of DPS 
eluates, the Murex was reactive for the 1:5 on the days 85, 138-152 and for 1:10 at days 146-
152. In contrast, the Monolisa was reactive to all DPS eluate dilutions starting from day 85 














A. HCV subtype 1a 
Murex Ag/Ab HCV combination                                Monolisa HCV Ag/Ab ULTRA 















































HCV subtype 1a Days since 1st bleed 
0 7 13 16 20 26 28 33 35 
HCV RNA + + + + + + + - - 
HCV Antibody - - + + + + + + + 
 
B. HCV subtype 2b 
Murex Ag/Ab HCV combination                                Monolisa HCVAg/Ab ULTRA       
















































HCV subtype 2b Days since 1st bleed 
0 20 22 85 131 135 138 146 152 
HCV RNA - + + - - - - - - 
HCV Antibody - - - + + + + + + 
 
Fig. 12: Evaluation of Murex and Monolisa Ag/Ab combination assays for DSS in 
different dilutions for HCV subtype 1a (A) and subtype 2b (B) seroconversion panels.   
 
For a panel of HCV subtype 1b serum reference samples, the Murex and Monolisa were 
reactive for all the days of bleed with undiluted sample (HCV RNA and antibody positive). 
Additionally, the Monolisa was reactive for all DSS eluate dilutions across the bleed. The 




A similar result was also obtained with a panel of HCV subtype 3a HCV RNA and antibody 
positive serum reference samples. The Murex and Monolisa were reactive at all time points of 
bleed with undiluted eluates and the Monolisa also for all dilutions tested. The Murex 
progressively lost its reactivity according to recency and dilution (Fig. 13B).  
 
Using a panel of HCV subtype 4d serum samples, the Murex and Monolisa performed akin to 
the subtype 1b panel (Fig. 13C).  
 
A. HCV Subtype 1b 
Murex Ag/Ab HCV combination                             Monolisa HCVAg/Ab ULTRA 





















































HCV subtype 1b Days since 1st bleed 
0 34 54 83 168 
HCV RNA + + + + + 
HCV Antibody + + + + + 
 
B. HCV Subtype 3a 
Murex Ag/Ab HCV combination                             Monolisa HCVAg/Ab ULTRA 



















































HCV subtype 3a Days since 1st bleed 
0   42 182 
HCV RNA +   + + 




C. HCV Subtype 4d 
Murex Ag/Ab HCV combination                             Monolisa HCVAg/Ab ULTRA 























































Fig. 13: Evaluation of Murex and Monolisa Ag/Ab combination assay for DSS in 
different dilutions using HCV subtype 1b (A), subtype 3a (B), and subtype 4d (C) 
seroconversion panels.   
 
In summary, for the plasma HCV seroconversion samples which were used as a reference for 
DSS eluates, the Murex became reactive earlier for antigen-positive bleeds. However, for the 
HCV antibody-positive eluates and dilutions thereof, the Monolisa demonstrated a superior 
sensitivity. 
 
In order to calculate the percentage of correct HCV positive test results, both assays were also 
used to screen clinical DSS eluates (n=1,102) obtained from newly diagnosed HIV-infected 
patients. Of these 123 (11.2%) and 105 (9.5%) DSS samples were found reactive by the 
Murex and Monolisa tests, respectively. Of those, 87 samples were found reactive in both 
assays (Table 1) representing 87/123 (70.7%) of the Murex positives and 87/105 (82.9%) of 
the Monolisa positives. Next, the ELISA reactive samples were screened by RT-qPCR to 
identify viremic cases. RNA negative reactive samples (presumed resolved infections) were 
subsequently analyzed by Western blot. Presence of HCV RNA or antibodies was confirmed 
for 77.2% (n=95/123) of the Murex reactive samples and for 98.1% (n=103/105) of the 
Monolisa reactive samples. For the Murex, the proportion of false reactive results was 
therefore higher compared to the Monolisa results (22.8% vs 1.9%) (Table 23).  
HCV subtype 4d Days since 1st bleed 
0      89 176 
HCV RNA +   + + 




Of the 64 reactive RT-qPCR-positive samples detected by the Murex, 54 were above the 
threshold of 1,000 IU/ml of HCV RNA (EASL, 2018) and 10 were below. Of the 65 
Monolisa-reactive samples only 5 were below 1,000 IU/ml of HCV RNA. This result is in line 
with our findings on the seroconverter panels indicating a higher sensitivity of the Murex 
assay for the detection of the HCV antigen.  
 
Table 23: Comparison of the performance of Murex and Monolisa in screening HCV 
coinfection in DSS of newly diagnosed HIV cases (n=1,102). 
 




















































4.2 RESULTS (PART II) 
Monitoring recency of infection helps to identify current transmission in vulnerable 
populations for effective disease control. In this study, an in-house avidity based HCV 
recency assay is established based on the Monolisa Anti-HCV PLUS Version 3 ELISA kit for 
use of DS/PS in order to distinguish recent and long-term infections. 
 
A first panel of DS/PS (n=218; genotype 1 n=170 and non-genotype 1 n=48) consisting of 
primary and at least one follow up sample was used to analyze the temporal changes of the AI 
over time. Sub-panels of longitudinal DS/PS (n=66) and acute cases (<26 weeks; n=34) were 
taken to calculate the MDRI and the FLTR, respectively. A second panel of DS/PS >104 
weeks (n=132) and a third panel of DS/PS prepared from resolved infections (>180 days since 
last positive; n=32) were used to calculate the FRR. 
 
4.2.1 Clinical characteristics of the study participants 
The relevant characteristics of the specimens included into the study are shown in Table 1. 
Among the 218 DS/PS tested, the majority was from infections with HCV genotype 1 
(77.9%). The median age of the study participants was 57 years (95% CI: 53-58).  
 
Table 24: Characteristics of study specimens 
 No. of samples % No. of individuals % 
Sex     
Male 150 68.8 43 67.2 
Female 64 29.4 20 31.3 
Unknown 4 1.8 1 1.5 
HCV genotype     
Genotype 1 170 77.9 51 79.7 
Genotype 3 18 8.3 6 9.4 
Genotype 4 30 13.8 7 10.9 
Estimated duration of infection 
    
<26 weeks 34 15.6 18 19.4 
26-52 weeks 28 12.8 16 17.2 
53-104 weeks 24 11 18 19.4 
>104 weeks 132 60.6 41 44 
HIV Status 
    
Positive 75 34.4 21 32.8 
Negative 143 65.6 43 67.2 
Evaluation panel 
    
Panel 1 (Longitudinal sample set) 218 100 64 100 
Sub panel a (for MDRI) 66 30.3 18 28.1 
Sub panel b (for FLTR) 34 15.6 18 28.1 
Panel 2 (for FRR) 132 60.6 41 64.1 




The increase of antibody avidity with time for genotype 1 and non-genotype 1 infections has 
been determined. Higher AI values were generally obtained for genotype 1 compared to non-




Fig. 14: Differential increase in HCV IgG antibody avidity over time for genotype 1 (A) 
and non-genotype 1(B) infections. An AI value was determined for 218 samples (from 64 
individuals) with HCV RNA ≥250 IU/ml. The median AI increases progressively with duration of 
infection for both genotype 1 and non-genotype 1 infections. n = number of samples 
 
4.2.2 Sensitivity, specificity and MDRI 
The longitudinal dataset (subpanel 1a; n=66) allowed estimating the probability for a recent 
infection by a mixed-effects logistic regression model for all genotypes with durations of 
infection of up to 4 years (Fig. 15). The sensitivity and specificity calculated by the model are 
only used to find the optimal AI and MDRI at AI cut-off values ranging from 20-45%. As 
shown in table 25, the sensitivity has increased from 72.4% at an AI cut-off of 20%, to 85.7% 
at an AI cut-off of 40%, while the specificity has increased from 72.9% at an AI cut-off of 
20%, to 88.2% at an AI cut-off of 40%. However, at an AI cut-off to 45%, both sensitivity 
and specificity have shown a decrease to 80.3% and 70%, respectively. The optimal AI of 
40% resulted in an MDRI of 364 days (95% CI: 223-485) for all genotypes with an accuracy 









Table 25: Sensitivity, specificity, accuracy and Mean Duration of Recent Infection 
(MDRI) according to selected cut-off avidity index (AI) values calculated for the 
longitudinal dataset (subpanel 1; n=66). 
 
AI cut-off (%) Sensitivity (%) Specificity (%) Accuracy (%) MDRI (days) (95% CI) 
All genotypes      
20 72.4 72.9 72.6 233 (149-449) 
25 78.3 79.3 78.8 264 (179-634) 
30 81.5 82.1 81.8 268 (183-695) 
35 82.2 80.9 81.5 325 (228-445) 
40 85.7 88.2 86.9 364 (223-485) 
45 80.3 70 75.1 517 (16-643) 
 
A mixed-effects logistic regression was used with the duration after infection and its square as 
fixed effects and the identifier of the patient as random effect. Since only few samples from 
patients with duration of infection longer than 2 years could be included, the confidence 




Fig. 15: Estimated probability for a positive avidity assay result as a function of the 
duration of the HCV infection estimated by the mixed effect logistic regression model. 
 
The FRR calculated using panel 2 (estimated time since infection of >104 weeks) for the 




(95% CI: 8.3-20.7) for all genotypes, 11.7% (95% CI: 6.6-19) for genotype 1, and 30.6% 
(95% CI: 9.1-61.4) for non-genotype 1 HCV infections. At the same AI cut-off value, the 
FLTR calculated using panel 1b (estimated time since infection of <26 weeks) was found to 
be 5.9 (0.7-19.7) for all genotypes, 8.3 (1-27) for genotype 1, and 0% (-) for non-genotype 1 
HCV infections (Table 26). 
 
Table 26: Estimated `False Recent Rate´ (FRR) and `False Long-term Rate (FLTR)´ 
calculated from the `long-term´ (> 104 weeks) and `recent´(< 26 weeks) infection panel 
according to the AI cut-off and genotype. 
 
 Avidity Index (%)  
 20 25 30 35 40 45 
FRR % 
(95% CI) 
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4.2.3 AI value for resolved infection 
Samples with a resolved infection were used in order to evaluate the performance of the assay 
in anti-HCV positive and HCV RNA negative cases. All the samples which had a minimum 
follow-up of 180 days since the estimated date of infection and before clearing the infection 
have a decline in the AI overtime. The mean AI values before (HCV RNA positive test) and 




Furthermore, of the 32 DS/PS specimen tested as resolved infection, 19 had AI values below 




Fig. 16: Changes in anti-HCV IgG AI values over time for individuals with resolved 
HCV infection. The observation period (2,863 days) is expressed as a minimum of 180 days before 
clearing the infection. The AI cut-off at 40% is indicated by a dashed line. Each symbol represents a 
single individual.  
 
In summary, this assay performs particularly well for genotype 1 reaching a high rate of 
correct discriminations between infections acquired less than a year before diagnosis and 
those acquired earlier by applying an AI cut-off of 40%. Due to a rapid decline in avidity post 














4.3 RESULTS (PART III) 
The objective of this part of the study was to determine the prevalence of HCV, HCV 
genotype/subtypes and RAS among a subset of new HIV-1 infections diagnosed between 
2015 and 2017 in Germany. For this purpose, a total of 6,097 DSS prepared from residual 
serum of newly HIV-diagnosed cases were sent to the RKI along with the anonymous report. 
This part of the study aimed to analyze HCV genotypes/subtypes and RAS in the main 
transmission groups: MSM, PWID and heterosexuals while considering sex and origin of the 
infected individuals. The total number of DSS tested in this study represents the general 
newly diagnosed HIV positive population in Germany (p<0.05) as shown by an 




Fig. 17: Comparison of samples analyzed in this study with the national statutory report 
with regards to some socio-demographic variables.  
 
4.3.1 HCV prevalence  
Of the total 6,097 tested samples, 416 (6.8%) were found to be ELISA reactive indicating the 
possible presence of anti-HCV antibody or HCV antigen in the patient samples. Analysis of 
these ELISA reactive samples by qRT-PCR for the presence of HCV RNA revealed 256 
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HCV specific antibodies among ELISA reactive and HCV-RNA negative samples, a further 
analysis of available 140 out of 160 samples was performed by Western blot. For the 
remaining 20 samples, there was no material available to carry out the Western blot analysis. 
Therefore, of the tested 140 samples, 120 (85.7%) became Western blot positive. Thus, 20 out 
of the 416 ELISA reactive samples (4.8%) could be identified as false ELISA-positives. The 
inability to confirm a positive fourth generation HCV-ELISA result by Western blot with an 
HCV RNA negative sample provides evidence for a false positve ELISA result (Rouet et al., 
2015). However, if the whole 160 samples would have been tested instead of only 140, a 
presumed 23 samples would have been false positives resulting in 393 correct ELISA 
reactives. This could mean that 3 out of the 20 ELISA reactive and RNA negative samples 
that could not have been tested would presumably be false positives. Since we do not know 
which these three samples are and in order to stay with lab results and avoid the possibility of 
introducing a bias when calculating the total ELISA reactives, only the 20 samples that were 
negative in the Western blot were removed from the 416 ELISA reactive samples resulting in 
396 diagnosed HCV coinfections for subsequent analyses. The proportion of viremic samples 
is 64.6% (256/396) and the remaining cases (n=140; 35.4%) are resolved HCV coinfections. 
 
Analysis of the samples in each of the diagnosis years showed the highest proportion of HCV 
seropositive persons (7.3%, n=153/2,087) and active infections (5.4%, n=112/2,087) in the 
year 2016 [comparison to 2015: 6.9% (n=136/1,980) and 4.2% (n=83/1,980), respectively]. 
However, in the diagnosis year 2017, there was a significant decline in the proportions of both 
HCV seropositive persons (5.3%, n=107/2,030; p<0.01) and active infections (3%, 
n=61/2,030; p<0.001) (comparison 2016: 7.3% and 5.4%, respectively) (Fig. 18). 
 
A study on samples with HIV new diagnosis from the pre-DAA study (October 2009 to June 
2011) by Johanna Riege (information extracted from her Bachelor thesis) (Riege et al., 2019) 
was taken for comparison with the analysis of this (post-DAA) study (2015-2017). The 
analysis of the pre-DAA study showed HCV antibody presence in 87 out of the 1,511 samples 
tested by the same ELISA. Of these, 81 (5.4%) samples could be further assayed using qRT-
PCR and 62 (4.1%) samples were tested positive indicating active infections. The proportion 
of resolved among all infections was 23.5% (Fig. 19). 
 
A comparison of the pre-DAA study with this study showed an increase in the proportion of 




However, a similar proportion of active infection was observed in both studies (4.1%, 




Fig. 18: Proportion of HCV ELISA reactive and active infections among HIV new 
diagnoses in the pre-DAA (2009-2011) and post-DAA (2015-2017) studies. n = number. 
 
The proportion of resolved infections among the diagnosed HCV coinfections has shown a 
significant increase (p<0.01) from the lowest proportion in the diagnosis year 2016 (26.8%; 
n=41/153) to a highest proportion in the year 2017 (43%; n=46/107). The increase in the 
overall proportion of resolved infections was also significantly higher (p<0.05) in this study 

















































Fig. 19: Proportion of resolved among all HCV resolved coinfections in HIV new 
diagnoses in the pre-DAA (2009-2011) and post-DAA (2015-2017) studies.  
 
4.3.2 Recent and longstanding HCV infections 
To estimate the trajectory of HCV infections in the country, an analysis of recent and long-
term infections was made using the established HCV recency assay. Accordingly, the 
proportion of HCV long-term infections was relatively higher in all diagnoses years (2015: 





Fig. 20: Distribution of recent and long-term HCV infections among HIV new diagnoses 

















































To further estimate the trends of HCV/HIV coinfection, an analysis of recent and long-term 
HCV/HIV coinfections was made using the established HCV recency assay. As a result, the 
proportion of long-term HCV infections in long-term HIV infections was higher in all 
diagnoses years (2015: 54%; 2016: 39%; 2017: 39%). However, the proportion of long-term 
HCV infections in long-term HIV infections has shown a significant decline (p<0.01) 
between the diagnoses years 2015 and 2016. On the other hand, during the same period, a 
significant increase (p<0.01) in the proportion of HCV long-term infections in HIV recent 
infections was observed. A lower proportion of HCV recent infections in HIV recent 






Fig. 21: Distribution of recent and long-term HCV infections in recent and long-term 
HIV infections in the year of diagnoses 2015-2017. 
 
4.3.3 HCV infection in different transmission groups 
In the samples analyzed for the diagnoses years 2015-2017, the main transmission groups 
were MSM (51.9%, n=3,164/6,097) followed by heterosexuals (27.7%, n=1,686/6,097) and 
PWIDs (3.5%, n=216/6,097). Although PWIDs accounted for only a small proportion of the 
study participants (3.5%), this group has the highest contribution of HCV seropositive 
samples (42.4%, n=168/396) as well as active (45.7%, n=117/256) and resolved (36.4%, 
n=51/140) HCV coinfections. On the other hand, in comparison with the other transmission 
groups, the PWIDs have the lowest contribution of HCV seronegative cases (0.8%, 
n=45/5681) (Fig. 22). Moreover, PWIDs are more likely to have HCV coinfection than the 
other transmission groups (OR=79.6, p<0.0001) (Table 27). The MSM group constitutes 
19.9% (n=79/396) of the tested HCV seropositive and the majority of the HCV seronegative 

























of the resolved HCV coinfections. The heterosexuals group constitutes 18.7% (n=74/396) of 
the HCV seropositive and 28.5% (n=1,608/5,681) of the seronegative cases. This group also 
includes 15% (n=38/256) and 25.7% (n=36/140) of the total active and resolved HCV 
coinfections, respectively. It is also important to also note that PWIDs, in comparison to other 
transmission groups, contribute to the majority of HCV positive, resolved (except for the 
diagnosis year 2015 wherein heterosexuals contribute the highest, 37.7%) and active HCV 
infections in the pre- and post-DAA studies and throughout the entire study period (2015-
2017) (Fig.22). 
  
In comparison with the pre-DAA study, in this study, there was a significantly higher 
proportion of DSS (17%, n=264/1,511 vs 28%, n=1,686/6,097; P<0.0001) and HCV 
seronegative cases obtained from heterosexuals (18%, n=255/1,422 vs 28%, n=1,608/5,681; 
P<0.0001) and a significantly lower proportion of HCV seronegative cases obtained from 




Fig. 22: Proportion of transmission groups and status of HCV infection among HIV new 
diagnoses in the pre-DAA (2009-2011) and post-DAA (2015-2017) studies. MSM = Men 








































































































































































































































































































































































































DAA Era, Year of Diagnosis and Status of HCV Infection 




Table 27: Odds ratio for HCV infection in transmission groups of HIV new diagnosis 
years 2015-2017.  
 
Transmission Group OR 95% CI p-value 
Men who have sex with men  0.12 0.09-0.16 p<0.0001 
People who inject drugs 79.6 55.6-113.8 p<0.0001 
Heterosexuals 0.42 0.32-0.55 p<0.0001 
 
A further look at the proportion of HCV coinfections in each transmission group revealed 
PWIDs to have the highest proportion (77.8%, n=168/216) followed by heterosexuals (4.4%, 
n=74/1,686) and MSM (2.5%, n=79/3,164). The proportion of HCV coinfection remained 
similar throughout the diagnoses years (2015-2017) in PWIDs (between 75.7 and 81%) and 
MSM (between 2.4 and 2.8%). In heterosexuals, however, there was a significant decline 
(p<0.05) between the diagnoses years 2015 and 2017 (5.6%, n=32/568 vs 3%, n=16/540). A 
comparison of the pre-DAA study with this study also showed a similar proportion in MSM 
(2.1% and 2.5%, respectively), PWIDs (76.5% and 77.8%, respectively) and a slight increase 




Fig. 23: Proportion of HCV infections belonging to a certain transmission group in the 
pre-DAA (2009-2011) and post-DAA (2015-2017) studies.  
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Analysis of resolved HCV coinfections among ELISA reactive individuals in each of the 
transmission groups showed the highest proportion in heterosexuals (53.7%, n=36/67) 
followed by MSM (42.5%, n=31/73) and PWIDs (31.3%, n=51/163). A further comparison of 
resolved infections through the diagnoses years (2015, 2016 and 2017) showed a similar 
proportion in MSM between the years 2015 and 2016 (36.4%; n=8/22 and 35.7%; n=10/28, 
respectively) and an increase (p=0.14) in the year 2017 (56.5%, n=13/23). For PWIDs and 
heterosexuals, compared to the year 2015, a decrease was observed in the year 2016 (36% vs 
28.4%; p=0.38 and 76.9% vs 28%; p<0.001, respectively) followed by an increase in the year 
2017 (30.4%; p=0.81 and 56.3%; p=0.07, respectively) (Fig. 24). 
 
Compared with the pre-DAA study, the proportion of resolved HCV coinfections in the post-
DAA study showed an increase in PWIDs (18.9%, n=7/37 vs 31.3%, n=51/163; p=0.13), 
heterosexuals (11.1%, n=1/9 vs 53.7%, n=36/67; p<0.05) and a slight increase in MSM 




Fig. 24: Proportion of resolved HCV coinfections among HIV new diagnoses in different 











































































































































































































































Based on the data obtained from the established recency assay, a further analysis on the extent 
of recent and long-term HCV/HIV coinfections was performed for the different transmission 
groups. Thus, a higher proportion of HCV long-term in HIV long-term cases were observed in 
MSM (37%, n=27/73), PWIDs (46.5%, n=72/155) and heterosexuals (45.5%, n=30/66). There 
were significant associations of PWIDs and heterosexuals with HCV long-term in HIV recent 





Fig. 25: Distribution of recent and long-term HIV infections in recent and long-term 
HCV infections in different transmission groups during the diagnoses years 2015-2017. 
 
Analysis on the trends of recent and long-term HCV/HIV infections was made for each of the 
main transmission groups. In the MSM, an increase in the proportions of HCV recent in HIV 
recent cases was observed in the years of diagnosis 2015 (0%, n=0/23), 2016 (11.5%, n=3/26) 
and 2017 (20.8%, n=5/24). The increase in MSM was significantly higher (p<0.05) between 
the diagnoses years 2015 and 2017. In the heterosexuals, although not significant (p>0.05), an 
increasing proportion of HCV long-term infections in HIV recent infections can be seen in the 
years 2015 (3.8%, n=1/26), 2016 (16.7%, n=4/24) and 2017 (18.8%, n=3/16) (Fig. 26). 
 





























HCV Recent/HIV Recent HCV Recent/HIV Long-term






Fig. 26: Overview of the proportions of recent and long-term HIV infections in recent 
and long-term HCV infections in different transmission groups for the HIV diagnoses 
years 2015-2017.  
 
4.3.4 HCV infection by sex groups 
To assess whether there is a difference in the prevalence of HCV coinfection in males and 
females, an analysis of HCV infection in relation to both sex groups was made for the current 
and pre-DAA studies. Among the overall samples tested for the diagnoses years 2015-2017, 
males account for the highest proportion of DSS tested (78.5%, n=4,785/6,097; p<0.0001), 
HCV seropositive (78.3%, n=310/396; P<0.0001) and seronegative individuals (78.5%, 
n=4,459/5,681; P<0.0001) as well as active (81.6%, n=209/256; P<0.0001) and resolved HCV 
coinfections (72.1%, n=101/140; P<0.0001). This has also been reflected in each of the 
diagnoses years (2015-2017) where males consistently dominate the proportion of HCV 
seropositive (80.9%; n=110/136, 77.1%; n=118/153 and 76.6%; n=82/107, respectively) and 
seronegative (78.4%; n=1,440/1,837, 77.7%; n=1,497/1,926 and 79.4%; n=1,522/1,918, 
respectively) individuals as well as resolved (71.1%; n=38/53, 73.2%; n=30/41 and 71.7%; 
n=33/46, respectively) and active (86.7%; n=72/83, 78.6%; n=88/112 and 80.3%; n= 49/61, 
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A high proportion of males in the pre-DAA study were also HCV seropositive (72.8%, 
n=59/81; P<0.0001) and had resolved (73.7%, n=14/19; P<0.0001) and active (72.6%, 
n=45/62; P<0.0001) infections. However, in comparison with the pre-DAA study, this study 
found a significantly higher proportion of DSS obtained from females (14.7%, n=222/1,511 
vs 21.3% n=1,301/6,097; P<0.0001) and a significantly lower proportion of HCV 
seronegative samples obtained from males (85.8%, n=1,220/1,422 vs 78.5%, n=4,785/6,097; 
p<0.0001) (Fig. 27A). 
 
A similar sub-analysis on the contribution of males and females among all HCV coinfections 
in the different time periods (2015-2017) showed a slight decrease (P>0.05) in males (80.9%, 
n=110/136; 77.1%, n=118/153 and 76.6%, n=82/107, respectively) and a gradual increase 
(p>0.05) in females (18.4%, n=25/136; 22.9%, n=35/153 and 23.4%, n=25/107, respectively) 
(Fig. 27B). 
 
Studies have shown that behavioral and social risks differ between male and female PWIDs 
(Folch et al., 2013, Tracy et al., 2014) and these differences could attribute to the differences 
in HCV infection between both sexes (Evans et al., 2003, Tracy et al., 2014). This study, 
therefore, assessed the contribution of male and female PWIDs among all HCV coinfections 
in the different time periods. The study found a significantly higher contribution of male 
PWIDs than female PWIDs in the post (33.8%, n=134/396 vs 8.6%, n=34/396; p<0.0001) and 
pre-DAA (33.3%, n=27/81 vs 14.8%, 12/81; p<0.01) studies. A further analysis across the 
diagnoses years 2015-2017 has shown a similar proportion in males (33.8%, n=46/136; 
35.3%; n=54/153 and 31.8%; n=34/107, respectively) and a gradual increase in females 
(5.1%, n=7/136; 9.2%, n=14/153 and 12.1%, n=13/107, respectively) (Fig. 27C). Thus, the 
analysis shows that male PWIDs contribute around 1/3 of all HCV coinfections in the 
analyzed time periods, while female PWIDs contribute only roughly 1/10. However, the 
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Fig. 27: Contribution of HCV coinfections by sex groups among HIV new diagnoses 
based on: A) different status of HCV infection B) ELISA reactive samples C) PWIDs of 
the pre-DAA (2009-2011) and post-DAA (2015-2017) studies.  
      
Analysis of the proportion of HCV coinfection among the tested samples in each of the sex 
groups indicated an equal proportion of coinfection in both sexes (6.5% each) (Fig. 28A). 
However, when looking at the coinfected PWIDs that constitute each group, male PWIDs 
have a slightly higher proportion (78.4%, n=134/171) of HCV coinfections than the female 
counterparts (75.6%, n=34/45) (Fig. 28B). A further analysis in each of the diagnosis years 
indicated a similar proportion of coinfection in males in the years 2015 and 2016 (7.1%, 
n=110/1,555 and 7.3%, n=118/1,622, respectively) and a significant decrease in the year 2017 
(5.1%, n=82/1,608, p<0.05) (Fig. 28A). Male PWIDs also demonstrate a similar pattern of 
coinfection (2015: 79.3%, 2016: 81.8% and 2017: 72.3%) (Fig. 28B). On the other hand, the 
proportion of coinfection in females remained similar in all diagnoses years (6%, each) except 
for the year 2017 (7.6%, n=35/463) in which case a non-significant increase (p=0.34) was 
observed (comparison year: 2015) (Fig. 28A). In contrast, an increasing proportion (p=0.1) of 
coinfection was observed in the female PWIDs throughout the diagnoses years 2015-2017 
(2015: 58.3%, 2016: 77.8% and 2017: 86.7%) (Fig. 28B). A comparison of the current study 
with the pre-DAA study showed a significant increase in the proportion of coinfection in 
males (4.9%, n=63/1,285 vs 6.5%, n=310/4,785; P<0.05) and a significant decrease in 






































females (10.8%, n=24/222 vs 6.5%, n=85/1,301; P<0.05) (Fig. 28A). Although not 
significant, a similar trend was also observed in male PWIDs (73%, n=27/37 vs 78.4%, 
n=134/171; p=0.47) and female PWIDs (85.7%, n=12/14 vs 75.6%, n=34/45; p=0.42) (Fig. 
28B). Overall, male and female PWIDs contribute roughly 3/4 of HCV coinfections in each of 








Fig. 28: Proportion of HCV coinfections among HIV new diagnoses in each of the sex 
groups based on A) ELISA reactive samples, and B) PWIDs of the pre-DAA (2009-2011) 











































































































This study also assessed if there is a difference in the proportion of resolved infections in 
males and females in the pre-DAA and post-DAA studies. The results show a higher 
proportion of resolved infections in the post-DAA than pre-DAA study in both males (32.6%, 
n=101/310 vs 23.7%, n=14/59 vs; p=0.17) and females (45.9%, n=39/85 vs 22.7%, n=5/22; 
p<0.05), respectively. A further comparison of resolved infections in males and females 
across the diagnoses years has shown a decrease in the years 2015-2016 (34.5% vs 25.4%; 
p=0.13 and 60% vs 31.4%; p<0.05, respectively) followed by an increase in the year 2017 




Fig. 29: Proportion of resolved HCV coinfections by sex groups in HIV new diagnoses in 
the pre-DAA (2009-2011) and post-DAA (2015-2017) studies.  
 
4.3.5 HCV infection by age groups 
The proportion of HCV coinfection has been investigated in different age groups of HIV new 
diagnoses in the current and pre-DAA study. Among the overall studied samples, a similar 
proportion of age groups was observed in the pre-DAA and post-DAA studies with the age 
group 30-39 years (30.5%; n=461/1,511 and 32.4%; n=1,978/6,097, respectively) to be the 
most frequently tested, followed by  the age groups 40-49 years (27.4%; n=414/1,511 and 
21.1%; n=1,288/6,097, respectively) and 25-29 years (15.3%; n=231/1,511 and 17.3%; 
























































                                 Pre-DAA study                              Post-DAA study 
 
                                      n=1,511                                             n=6,097 
 
Fig. 30: Proportion of dried serum spots tested in different age groups of pre-DAA 
(2009-2011) and post-DAA (2015-2017) studies.  
 
In both pre-DAA and post-DAA studies, the largest contribution to the HCV seropositive 
individuals was made by the age group of 30-39 years old (35.8%, n=29/81 and 45.2%, 
n=179/396, respectively), followed by the age groups 40-49 years old (23.5%, n=19/81 and 
26.3%, n=104/396, respectively) and 25-29 years old (22.2%, n=18/81 and 12.6%, n=50/396, 
respectively) (Fig. 31A). Moreover, age groups 30-39 years old and 40-49 years old were 
more likely to have HCV infection than the other age groups (OR=1.76, P<0.0001; and 
OR=1.32, P<0.05, respectively) (Table 28). Compared with the pre-DAA study, the 
proportion of HCV infection in the post-DAA study has shown a significant decrease for the 
age groups 20-24 (p<0.05) and 25-29 (p<0.05) years old. On the other hand, there was an 
increase in the age groups 30-39 (p=0.12) and 40-49 years old (p=0.6), 50-59 (p=0.31) and 
>69 (p=0.37) years old (Fig. 31A). 
 
In order to assess whether HCV coinfection in different age groups is consistent with the 
demographic profile of injecting drug use, this study has compared the contribution of HCV 
coinfected PWIDs of various age groups to the total HCV infection in pre-and post-DAA 
studies. Thus, similar to the results shown in Fig. 31A, a higher proportion of coinfection in 
PWIDs was observed in the age group 30-39 years old (20.5%, n=81/396) followed by the 
age groups 40-49 (12.1%, n=48/396) and 25-29 years old (6.3%, n=25/396). In comparison 
with the pre-DAA group, there was a decline in the proportion of HCV infection in all age 
groups except for the age groups 40-49 (6.2%, n=5/81 vs 12.1%, n=48/396; p=0.12) and 60-

























of 30-39 years old contribute around 1/5 of all HCV infections in both pre-DAA and post-








Fig. 31: Contribution of various age groups to all HCV coinfections in HIV new 
diagnoses based on: A) ELISA reactive samples, and B) PWIDs of the pre-DAA (2009-



























































































































































































































































































































































Table 28: Odds ratio for HCV infection by age groups of HIV new diagnosis years 2015-
2017. 
 
Age groups (Years) OR 95% CI p-value 
20-24 0.19 0.09-0.39 p<0.0001 
25-29 0.65 0.48-0.89 p=0.0078 
30-39 1.76 1.42-2.17 p<0.0001 
40-49 1.32 1.04-1.68 p=0.0196 
50-59 0.71 0.5-1.01 p=0.0586 
60-69 0.57 0.28-1.17 p=0.1295 
>69 0.67 0.2-2.09 p=0.4747 
 
Analysis of the proportion of HCV coinfection among the tested samples in each age group 
shows the largest proportion in the age groups of 30-39 (9%, n=179/1,978) and 40-49 (8.1%, 
n=104/1,288) years old. Moreover, in comparison with the pre-DAA study, the proportion of 
HCV infection in the post-DAA study has shown a decrease for the age groups 20-24 
(p=0.21), 25-29 (p=0.06) and >69 (P=0.35) years old. On the other hand, there was an 
increase in the age groups 30-39 (p=0.06) and 40-49 years old (p<0.05), 50-59 (p=0.42) and 
>69 (p=0.35) years old (Fig. 32A).  
 
This study has also assessed the proportion of HCV coinfected PWIDs in each of the HCV 
coinfected age groups in the pre- and post-DAA studies. Although, the total number of pre-
DAA PWIDs in the age groups of 20-24 (n=1), 50-59 (n=2) and 60-69 (n=0) years old were 
too low for comparison with the post-DAA PWIDs, the proportion of HCV coinfection in the 
PWIDs of other age groups was generally high in both studies (50% to 83.3%). In addition, 
there was a non-significant increase in the proportion of HCV coinfection in the post-DAA 
PWIDs in the age groups 30-39 (76%, n=19/25 vs 81%, n=81/100; p=0.57) and 40-49 (50%, 
















Fig. 32: Proportion HCV infection among HIV new diagnosis in different age groups of 
A) ELISA reactive samples, and B) PWIDs of the pre-DAA (2009-2011) and post-DAA 


































































































































































































































































































































































A comparison of HCV resolved infections in the different age groups of pre-DAA and post-
DAA studies has shown an increase in the age groups 20-24 (33.3%, n=2/6 vs 54.5%, n=6/11; 
p=0.41), 25-29 (5.6%, n=1/18 vs 32%, n=16/50; p<0.05) 30-39 (5.6%, n=1/18 vs 30.2%, 
n=54/179; p=0.77) and 40-49 (21.1%, n=4/19 vs 41.3%, n=43/104; p=0.09) years. Although 
the total numbers of ELISA reactives in the age groups 50-59 (n=5) and 60-69 (n=3) and >69 
(n=0) of the pre-DAA study were too low for comparison with the current study (Fig. 33A), 
the proportion of resolved HCV infections have been shown to increase (p>0.05) for these age 
groups and for the age group 40-49 (p>0.05) in the years 2015-2017. Despite a slight decrease 
in the year 2016 (22.5%; n=16/71), the proportion of resolved infections for the age group 30-
39 years old remained similar in the years 2015 and 2017 (35.9%, n=23/64 vs 34.1%, 

































































































































































































Fig. 33: Proportion of resolved HCV coinfections among HIV new diagnoses in different 
age groups of A) the pre-DAA and post-DAA studies, and B) diagnoses years 2015-2017.  
 
4.3.6 HCV infection by country of origin 
An assessment of HCV coinfection by the country of origin was possible in different time 
periods based on the statutory anonymus reports provided by the diagnostic laboratories to the 
RKI. This analysis is particularly important as there has been a huge influx of asylum seekers 
from high endemic countries in the years 2015 and 2016 (Grote, 2018) which can have an 
impact on the viremic pool of the country.   
 
From the total 6,097 tested samples, 55% (n=3,355/6,097) of the persons are Germans and 
40.6% (n=2,477/6,097) were foreigners by origin. For the remaining 4.4% (n=265/6,097) of 
the persons, the country of origin is not reported (Fig. 34). Germans also constitute a higher 
proportion than foreign nationals in the diagnoses years 2015 (53.2%, n=1,054/1,980 vs 
43.6%, n=863/1,980), 2016 (57.5%, n=1,199/2,087 vs 38.7%, n=808/2,087) and 2017 (54.2%, 
n=1,102/2,030 vs 39.7%, n=806/2,030) (Fig. 35). A similar order in the proportion of 
Germans (62.3%; n=941/1,511) and foreign nationals (23.2%; n=351/1,511) was also reported 

































































































































































































































      
                                  n=1,511                                                  n=6,097 
Fig. 34: Proportion of regional origins of different nationals among dried serum spots 
tested in the pre-DAA (2009-2011) and post-DAA (2015-2017) studies.  
 
In the pre-DAA and post-DAA studies, people from Africa (8.5%; n=129/1,511 and 19.6%; 
n=1,196/6,097, respectively) and Central Europe (3.4%; n=52/1,511 and 6.1%; n=372/6,097, 
respectively) represent the largest group of persons with a foreign origin (Fig. 34). In the same 
manner, people from the two regions contribute the largest share of foreign nationals in the 
diagnoses years 2015-2017 (Fig. 35). 
 




Fig. 35: Proportions of regional origins of different nationals among dried serum spots 
tested in the diagnoses years 2015-2017.  
 
Compared to Germans, foreign nationals had a significantly higher proportion of HCV 
seropositive individuals (8.8%, n=219/2,477 vs 4.6%, n=156/3,355; p<0.0001). Moreover, 




























































P<0.0001) (Table 29). In consistent with this study, the pre-DAA study also showed foreign 
nationals compared to Germans to have a significantly higher proportion of HCV seropositive 




Fig. 36: Origin and status of HCV infection in all DSS samples and among HIV new 
diagnoses in the pre-DAA (2009-2011) and post-DAA (2015-2017) studies.  
 
Among the foreign nationals, the highest proportion of HCV coinfection was found in the 
people from E. Europe (38.3%) and C. Europe (11.3%). In comparison to the pre-DAA study, 
in this study, the proportion of HCV infection has slightly increased in the people from 
foreign counties (8%; n=28/351 vs 8.8%; n=219/2,477; p=0.61), S/SE Asia (6.1%; n=2/33 vs 
8.4%; n=16/190; p=0.65), W. Europe (2.1%; n=1/47 vs 6.1%; n=10/164; p=0.27) and C. 
Europe (9.6%; n=5/52 vs 11.3%; n=42/372; p=0.71). For German nationals, the proportion of 
infection was nearly similar in both studies (4.4%; n=41/941 vs 4.6%; n=156/3,355; p=0.79). 
A decrease in the proportion of infection was also noted in people from Africa (2.3%; 
n=3/129 vs 1.9%; n=23/1,196; p=0.75) and E. Europe (42.1%; n=16/38 vs 38.3%; n=124/324; 
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to have HCV infection than other nationalities (OR=4.47, P<0.0001 and OR=4.18, P<0.0001, 




Fig. 37: Proportion of HCV infections by country of origin among HIV new diagnoses in 
the pre-DAA (2009-2011) and post-DAA (2015-2016) studies.  
 
Table 29: Odds ratio for HCV infection in different nationalities of HIV new diagnosis 
years 2015-2017.  
 
Country of origin OR 95% CI p-value 
German 0.22 0.17-0.28 p<0.0001 
Foreigner 4.47 3.51-5.71 p< 0.0001 
Africa 0.04 0.02-0.06 p< 0.0001 
S/SE Asia 0.47 0.28-0.8 p=0.0053 
E. Europe 4.18 3.22-5.44 p<0.0001 
W. Europe 0.33 0.17-0.63 p=0.0009 
































































































































































































































As depicted in Fig. 38, the proportion of HCV infection has decreased throughout the 
diagnoses years 2015 to 2017 in foreign nationals (11.4%; n=90/787, 10.1%; n=75/740 and 
7.7%; n=54/699, respectively) and in people from S/SE Asia (13.9%; n=10/72, 5.6%; n=3/54 
and 4.7%; n=3/64, respectively), E. Europe (41.9%; n=49/117, 37.6%; n=41/109 and 34.7%; 
n=34/98, respectively) and C. Europe (13.4%; n=16/119, 13.3%; n=18/135 and 8.2%; n=8/98, 
respectively). In Germans, compared to the diagnosis year 2015, the proportion has shown a 
significant increase in the year 2016 (3.8%, n=40/1,054 vs 6%, n=72/1,199; p<0.05) followed 
by a significant decrease in the year 2017 (4%, n=44/1,102; p<0.05). On the other hand, in 
comparison to the diagnosis year 2015, the proportion of HCV infection has shown a 





Fig. 38: Proportion HCV infection by country of origin among HIV new diagnoses years 
2015-2017.  
 
Analysis of transmission groups among different nationalities has shown PWIDs to be the 
dominant group in all nationalities, except for the people from Africa and West Europe in 
which case the dominant groups were heterosexuals (69.6%, n=16/23; p<0.01) and MSM 





















































































































































































































































































accounts as a second major transmission group next to the PWIDs (44.2%, n=69/156; p=0.51) 




Fig. 39: The proportion of different transmission groups by country of origin in HCV 
seropositive individuals in the HIV new diagnoses years 2015-2017.  
 
As PWIDs contribute to the largest share of HCV coinfection in German and foreign nationals 
(Fig. 39), a comparison with PWIDs from the pre-DAA study was made in order to find out 
the change in the level of coinfection in the post-DAA era. In this study, the proportion of 
HCV coinfection was generally high in the PWIDs of all nationalities (40%-87.5%). Although 
there were smaller numbers of samples for some groups of the pre-DAA study, a comparison 
with this study shows a similar proportion in German nationals (76%, n=19/25 vs 75%, 
n=69/92; p=0.92) and an increase in foreign (72.2%, n=13/18 vs 78.9%, n=90/114; p=0.53), 
African (33.3%, n=1/3 vs 40%, n=2/5; p=0.86) and E. European (80%, n=8/10 vs 85.3%, 









































Fig. 40: Proportion of injection drug users by their origin to the HCV coinfected cases 
among HIV newly diagnoses of pre-DAA (2009-2011) and post-DAA (2015-2017) studies.  
 
A comparison in the proportion of HCV resolved infections was made with the pre-DAA 
study in order to assess the changes in these cases after the introduction of DAAs. Thus, in 
comparison with the pre-DAA study, the proportion of HCV resolved infection in the post-
DAA study has shown an increase in all nationalities. The increase in the proportion of 
resolved infection was particularly significant in people of foreign (3.6%, n=1/28 vs 34.2%, 
n=75/219; p<0.01) and Eastern European (0%, n=0/16 vs 32.3%, n=40/124; p<0.01) origin 
(Fig. 41A).   
 
A further comparison of resolved infections among the diagnoses years (2015-2017) has 
shown a decrease in the diagnoses years 2015-2016 in Germans (40%, n=16/40 Vs 36.1%, 
n=26/72; p=0.68), foreigners (40%, n=36/90 vs 20%, n=15/75; p<0.01) and Eastern 
Europeans (32.7%, n=16/49 vs 22%, n=9/41; p=0.26) followed by an increase in the year 
2017 (38.6%, n=17/44; p=0.78, 44.4%, n=24/54; p<0.01 and 44.1%, n=15/34; p<0.05, 
respectively). However, a gradual and a non-significant decrease (p>0.05) was observed in 
Africans throughout the study period (75%; n=6/8, 50%; n=4/8 and 28.6%; n=2/7, 

















































































































































































































Fig. 41: Proportion of resolved HCV coinfections by country of origin among HIV new 







































































































































































































































































4.3.7 Genotype and subtype distribution 
For the diagnoses years 2015-2017, the genotype and subtype could be successfully 
determined for 91.1% (n=233/256) of samples with an active HCV infection. For 6.6% 
(n=17/256) of the samples, the genotype and subtype could not be successfully tested with a 
nested PCRs in the NS5B region of the HCV genome and for the remaining 2.3% (n=6/256) 
there was no DSS to carry out the nested PCRs. Overall, 23 of the 256 qPCR-positive samples 
(9%) could not be geno-/subtyped. The viral load of samples that were successfully geno-
/subtyped ranged from 3.45E + 01(IU/ml) to 4.05E + 07 (IU/ml). The mean viral load was 
1.59E + 06 (95%CI: 1.1E + 06 IU/ml - 2.08E + 06 IU/ml).   
 
Within the overall studied samples in the post-DAA study (n=233), genotype 1 was the most 
frequently observed with 57.1% (subtype 1a: 33.9%, subtype 1b: 22.3%, subtype 1e: 0.4% 
and an unidentified subtype: 0.4%) followed by genotype 3 with 33.5% (exclusively subtype 
3a), genotype 4 with 7.7% (subtype 4a: 3%, subtype 4b: 0.4%, subtype 4d: 3.9% and subtype 
4k: 0.4%) and genotype 2 with 1.7% (subtype 2a: 1.3% and subtype 2 a/b: 0.4%). For the pre-
DAA group, 47/62 active HCV infections were successfully genotyped. Similar to this study, 
genotype 1 was the most frequently observed with 55% (subtype 1a: 38% and subtype 1b: 
17%) followed by genotype 3 with 30% (exclusively subtype 3a). Although statistically not 
significant, there was a decrease in the proportion of genotype 1 infections in this study 
compared to the pre-DAA study (70.2% vs 57.1%; p=0.09) (Fig. 42).    
 
          
 
 
Fig. 42: The overall subtype distribution of active HCV infections in the pre-DAA (2009-































The proportion of each subtype was relatively similar across the years 2015-2017. However, 
in comparison to the year 2015, a significant increase in the proportion of genotype 1 
infection (47.2%; n=34/72 vs 63.7%; n=65/102; p<0.05) and a decrease in the proportion of 
genotype 3 (subtype 3a) infection (39%; n=28/72 vs 30%; n=31/102; p=0.21) has been 
observed in 2016 (Fig. 43).   
 
           
     
  
 
Fig. 43: Subtype distribution in the active HCV infections from the HIV diagnoses years 
2015-2017.  
 
Analysis of HCV subtypes in different transmission groups revealed a significant association 
of subtype 1a with MSM (57.5%; n=23/40; p<0.01). Although not significant, there were 
relatively high proportions of subtype 3a (39.3%; n=42/107; p=0.12) and subtype 1a (33.6%; 
n=36/107; p=0.06) in PWIDs as well as subtype 3a (42.9%; n=15/35; p=0.24) and subtype 1b 
(34.3%; n=12/35; p=0.08) in heterosexuals. In comparison to the pre-DAA study, subtype 4c 
has shown a significant decrease in MSM (20%, n=2/10 vs 0%, n=0/40; p<0.01). In a similar 
comparison, although not significant, an increase in the proportions of subtype 1a in MSM 
(40%, n=4/10 vs 57.5%, n=23/40; p=0.32) and subtype 1b in heterosexuals (20%, n=2/10 vs 
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Fig. 44: Proportion of HCV subtypes among HIV new diagnosis in different 
transmission groups of the pre-DAA (2009-2011) and post-DAA (2015-2016) studies. St = 
Subtype. 
 
Analysis of HCV subtypes by country of origin in this study shows a significant association 
of subtype 1a with Germans (50%, n=43/86; p<0.01) as well as subtype 1b (30.5%, n=40/131; 
p<0.05) and subtype 3a (39.7%, n=52/131; p<0.01) with foreigners. In comparison with the 
pre-DAA study, a significant decrease of subtype 4c (9.5%, n=2/23 vs 0%, n=0/86; p<0.01) 
and a non-significant increase of subtype 1b (0%, n=0/23 vs 11.6%, n=10/86; p=0.09) were 
observed among German nationals. A non-significant increase of subtype 1a (13.6%, n=0/23 
vs 22.1%, n=29/131; p=0.35) was also observed among foreign nationals in the post-DAA 
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Fig. 45: Proportion of HCV subtypes among HIV new diagnoses in Germans and 
foreigners in the pre-DAA (2009-2011) and post-DAA (2015-2016) studies.  
 
4.3.8 Analysis of resistance associated substitutions 
The evaluation and interpretation of existing RAS was performed using a web tool 
(geno2pheno). HCV sequences were classified into the corresponding genomic regions as 
sensitive, reduced susceptibility and resistant to the individual drugs approved for the subtype. 
In addition, RAS indicating substitution to the wild type reference sequence, but not 
associated with decreased susceptibility to DAAs (herein after referred to as "DAA-relevant 
position substitution") were included in the analysis. 
 
The following analysis includes only samples for which sequence information is available on 
all DAA-relevant genome regions (n=160). In each of the figures below, the highest type of 
resistance against DAAs is shown. If, for example, two RAS are observed within a single 
sample, one which leads to reduced susceptibility and one leading to resistance, only the RAS 
leading to resistance were considered. 
 
Based on all classes of medication, the total RAS proportion was found to decrease from 69% 













































diagnoses years 2016 and 2017, respectively. The proportion of resistance at a DAA-relevant 
position was similar for the diagnoses years 2015 and 2016 (21.4%; n=9/42 and 21.5%; 
n=17/79, respectively). However this has shown a decline (p=0.25) to 12.8% (n=5/39) in the 




Fig. 46: Overview of the proportions of detected RAS in active HCV infections from the 
diagnoses years 2015-2017 in relation to all drug classes.  
 
Among the RAS shares in individual HCV subtypes, the highest proportion can be found 
within subtype 1a (2015: 58.3%, 2016: 79.3%, 2017: 78.6%), subtype 1b (2015: 100%, 2016: 
81%, 2017: 75%) and subtype 3a (2015: 77.8 and 2016: 24%) (Fig. 47).  
 
In the subtype 1a samples, 33.3% (2015), 34.5% (2016), 42.9% (2017) of the HCV sequences 
show resistance at a DAA-relevant position. A high proportion of RAS in the St-1a samples 
(2016: 25%; 2017: 41.4%; 2018: 35.7%) can only be attributed to "substitutions in a DAA-
relevant position." In the case of the subtype 1b, the proportion of substitutions at a DAA-
relevant position showed a significant decrease (p<0.05) in the diagnoses years 2015 (50%) 
and 2016 (9.5%), respectively. On the other hand, the proportion of samples whose HCV 
sequence has a resistance to DAAs was relatively similar throughout the study period (2015: 
25%, 2016: 28.6%, 2017: 25%). The proportion of RAS that has a reduced effect on DAAs 





























Year of HIV New Diagnosis




2015 (25%) and 2017 (37.5%). In the subtype 3a samples, a significantly higher (p<0.001) 
proportion of RAS was mainly detected in the diagnosis year 2015 (77.8%) compared with 
the year 2016 (24%). The RAS in both diagnoses years were due to substitutions at a DAA-
relevant position (2015: 55.6% and 2016: 16%, P<0.01). There was no RAS detected in the 
diagnosis year 2017. During the diagnoses years 2015-2016, a decrease (P=0.16) in the 
proportion of resistance to DAAs (16.7% and 4%, respectively) and a slight decrease in RAS 
that has a reduced effect on DAAs (5.6% and 4%, respectively) were observed. In subtype 
4a/d samples, RAS were only detected in the diagnosis year 2016 and were exclusively (50%; 




Fig. 47: Overview of the proportions of detected RAS in active HCV infections from the 
HIV diagnoses years 2015-2017 in the individual HCV subtypes.  
 
The proportion of RAS leading to reduced efficacy or resistance to DAAs in the subtype 1a 
and subtype 1b samples is high in the diagnosis years 2015-2017, especially in the NS3 region 
(subtype 1a: 33.3%, 37.9%, 42.9%, respectively and subtype 1b: 37.5%, 38.1%, 25%, 
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Fig. 48: Overview of the proportions of samples with reduced efficacy or resistance to 
DAAs in active HCV infections from the HIV diagnoses years 2015-2017 in the 
individual subtypes.  
 
In the subtype 1a samples, limited efficacy against DAAs is mainly due to polymorphic Q80K 
substitution in the NS3 region, which favors resistance to the drugs Simeprevir (2015: 33.3%, 
2016: 34.5%, 2017: 42.9%) and Voxilaprevir (2015: 33.3%, 2016: 34.5%, 2017: 42.9%) (Fig. 





























































































Fig. 49: Proportions of RAS with reduced efficacy or resistance to DAAs per approved 
drug and genomic regions of HCV subtype 1a samples in the HIV new diagnoses years 
2015-2017. ASV= Asunaprevir, GZV= Grazoprevir, SMV= Simeprevir, VOX= Voxilaprevir, DCV= 
Daclatasvir, ELV= Elbasvir, LDV= Ledipasvir, OBV= Ombitasvir, VEL= Velpatasvir.  
 
In the subtype 1b samples, the reduced efficacy is caused by the Y56F substitution in the NS3 
region (2015: 37.5%, 2016: 33.3%, 2017: 25%), which has a reduced efficacy against the drug 
Grazoprevir (Fig. 50). In addition, there is also an increasing proportion of RAS in the NS5B 
region, which results in resistance to DAAs (2015: 12.5%, 2016: 38.1%, 2017: 50%) (Fig. 
48). This is mainly due to the increasing proportion of S556G substitution in the NS5B region 
(2015: 0%, 2016: 23.8%, 2017: 25%) conferring resistance to the drug Dasabuvir and L159F 
substitution in the NS5B region (2015: 12.5%, 2016: 23.8%, 2017: 37.5%), which causes 
reduced efficacy of the drug Sofosbuvir (Fig. 50). In addition, an increasing and high 
proportion of the substitution C316N was found (2015: 12.5%; 2017: 42.8%; 2018: 62.5%; 
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Fig. 50: Proportions of RAS with reduced efficacy or resistance to DAAs per approved 
drug and genomic regions of HCV subtype 1b samples in the HIV new diagnoses years 
2015-2017. ASV= Asunaprevir, GZV= Grazoprevir, PTV=Pibrentasvir, SMV= Simeprevir, VOX= 
Voxilaprevir, DCV= Daclatasvir, ELV= Elbasvir, LDV= Ledipasvir, OBV= Ombitasvir, VEL= 
Velpatasvir, DSV=Dasabuvir, SOF=Sofosbuvir.  
 
In the subtype 3a samples, RAS were only detected in the samples from the diagnoses years 
2015 and 2016 (77.8% and 24%, respectively; p<0.001) (Fig. 48). This is mainly due to the 
A30K substitution in the NS5A region, which results in reduced efficacy or resistance to all 
NS5A inhibitors approved for subtype 3a at a similar proportion (2015: 11.1% and 2016: 4%). 











































































































































Fig. 51: Proportions of RAS with reduced efficacy or resistance to DAAs per approved 
drug and genomic regions of HCV subtype 3a samples in the HIV new diagnoses years 
2015-2017. DCV= Daclatasvir, ELV= Elbasvir, LDV= Ledipasvir, PIB=Pibrentasvir, VEL= 
Velpatasvir. 
 
Predominantly, RAS which resulted in reduced efficacy or resistance to DAAs are found in 
only one genomic region and thus affect the efficacy of only one class of drug. However, 
especially in the subtype 1b samples, RAS that limit the efficacy of DAAs may also be 
present in two (2015: 50%, 2016: 6.7% and 2017: 20%) or in all of the three genome regions 
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Fig. 52: Overview of the proportions of samples with reduced efficacy or resistance to 
DAAs in active HCV infections from the HIV diagnoses years 2015-2017 in relation to 
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5.1 DISCUSSION (PART I) 
A precise and early diagnosis of an acute HCV infection is critical because it provides a 
chance of cure by antiviral therapy and helps to avoid transmission to uninfected individuals. 
HCV antigen and antibody combination assays have been developed and introduced as cost-
effective alternative methods in addition to nucleic acid testing for early/rapid diagnosis by 
reducing the window period. This study evaluated the diagnostic performance of Murex and 
Monolisa antigen/antibody combination assays for DS/PS eluates using plasma and serum as 
reference samples. In addition, longitudinal HCV panels and clinical DSS eluates were used 
to screen for previous or current HCV coinfections in newly diagnosed HIV-infected patients.  
 
For the seroconversion plasma panels of subtypes 1a and 2b, the Murex test became reactive 
for an earlier bleed than the Monolisa test. The results from (Laperche et al., 2015) also 
demonstrated the relatively better performance of the Murex test in reducing the window 
period by 45% (about 36.4 days) compared to a reduction by 38% (about 40.5 days) by the 
Monolisa test. The Monolisa, on the other hand, was relatively more reactive to antibody 
positive bleeds than the Murex counterpart.  
 
The positive reactivity of the Murex test for the serum samples of subtypes 1b, 3a, and 4d also 
shows its comparable performance to that of the Monolisa test in the detection of antigen and 
antibody positive samples. However, for the diluted DSS eluates, the Murex was generally 
reactive for lower dilutions in the early days of bleed and for almost all dilutions at later time 
points. The Monolisa test, on the other hand, was reactive to all dilutions across the duration 
of bleed indicating its superior sensitivity and potential use for HCV screening in DS/PS.  
 
Application of both assays to screen HCV coinfection in DSS eluates of newly diagnosed 
HIV-cases resulted in a relatively higher proportion of ELISA reactive samples by the Murex 
test than the Monolisa test. However, as confirmed by RT-qPCR and Western blot, the Murex 
was found to generate more false-positive results than the Monolisa. The overall correct 
positive rate of 98.1% in this study by the Monolisa test corresponds to those reported in 
similar studies (Courouce et al., 2000, Muerhoff et al., 2002, Nubling et al., 2002, Shah et al., 
2003, Laperche et al., 2005a, Leary et al., 2006, Odari et al., 2014) pointing towards a better 
sensitivity and specificity for the use of DSS eluates in HCV screening compared to the 




with the clinical DSS is a previously reported cross-reactivity with anti-HIV antibodies 
(Everett et al., 2007). 
 
A limitation in our analysis was that the panels which we used for subtypes 1b, 3a, and 4d 
were only based on antibody and RNA positive samples. Therefore, the performance of the 
two assays during the window period (antigen-positive and antibody-negative) was not tested 
for these subtypes. Moreover, even though regarded highly unlikely, we can formally not rule 
out that the earlier reactivity of the here tested RNA positive and yet antibody negative 
samples by the Murex assay is due to a false positive antigen based reactivity.  
 
In conclusion, although we could not intensively test for antigen sensitivity for all HCV 
subtypes, our results for the plasma samples of subtypes 1a and 2b indicate that the Murex 
assay performs better for the detection of antigen positive samples, while the Monolisa assay 
is more suited for antibody detection. On the other hand, the Monolisa assay provides more 
consistent and reliable results for the detection of different HCV subtypes in dilutions of 
DS/PS eluates compared to the Murex assay. The Monolisa assay, therefore, indicates its 
potential use for HCV screening in DS/PS. However, a confirmatory test for Monolisa 
reactive samples by Western blot and RT-qPCR is recommended in this setting as well. 
Furthermore, the Murex can serve as an additional diagnostic tool to narrow the window 
period. Hence, HCV screening strategies involving both DS/PS and a combined antigen-
antibody assays could be a method of choice as these tests provide a cheaper and simpler 














5.2 DISCUSSION (PART II) 
The usefulness of DS/PS to detect viral infections has been established for surveillance 
purposes (Monleau et al., 2010, Rodriguez-Auad et al., 2015, Hauser et al., 2017, 
Maldonado-Rodriguez et al., 2017). In this study, for the first time, we have established an in-
house antibody-avidity based HCV recency assay for the use of DS/PS in order to distinguish 
between recent and longstanding infection. 
 
An evaluation panel of longitudinal DS/PS of acute and chronic HCV infections was used to 
analyze the temporal changes of AIs over time in genotype 1 and non-genotype 1 infections. 
For both genotypes, stronger antibody avidity is associated with the higher number of days 
post infection. This is consistent with the findings of the previous studies which were based 
on whole blood (serum) analysis (Croom et al., 2006, Tuaillon et al., 2010, Hope et al., 2011, 
Shepherd et al., 2013). There was a sharp increment in AI value for genotype 1 compared to 
non-genotype 1 infections and this is consistent with the report of Shepherd et al (Shepherd et 
al., 2018). 
 
The FRR of 13.6% (specificity of 86.4%), as calculated from the chronic infection panel 
(panel 2) for all genotypes at an optimal AI cut-off of 40% and with an estimated duration of 
<104 weeks, was lower compared to other studies which reported a specificity of 100% at AI 
cut-off 43% (Gaudy-Graffin et al., 2010) and 99% at AI cut-off of 20% (Shepherd et al., 
2013). Furthermore, a prolonged HCV seroconversion has been associated with HIV 
coinfection (Thomson et al., 2009). Along those lines, a study by Patel et al (Patel et al., 
2016) reported a specificity of 99% and 92% at an optimal AI cut-off of 20% among HIV-
negatives and HIV-positives, respectively. The rather high FRR (low specificity) in our assay 
evaluation might have been due to the significant proportion (34%) of samples from HIV 
coinfected individuals in addition to the use of DS/PS instead of serum. Furthermore, 
differences in the assay characteristics can also be explained by the use of the Monolisa™ 
Anti-HCV PLUS Version 3 in our study in contrast to the Ortho HCV Version 3 ELISA kit 
utilized in several previous studies. Dissimilarities in the coated antigen are presumably of 
paramount importance in this respect. 
 
The FLTR (100-sensitivity) at the optimal AI cut-off 40% and with an estimated duration of 
<26 weeks was lower for genotype 1 (8.3%; sensitivity of 91.7%), non-genotype 1 (0%; 




sensitivity reported by Shepherd and coworkers (2018) for the same duration of infection at 
an AI cut-off of 20% (36%, 65%, and 48%, , respectively). The difference could be explained 
by the different AI cut-off (generally resulting in a lower sensitivity, but higher specificity) 
and the smaller number of recently infected patient samples in our application panel compared 
to the above study (n=34 and n=120, respectively). 
 
Patients who cleared the infection after a minimum of 180 days resulted in a decline of AI 
values over time. Previous studies have also shown lower AI values in these groups of 
patients compared to patients with chronic HCV infection (Hedman and Seppala, 1988, 
Kanno and Kazuyama, 2002, Klimashevskaya et al., 2007, Gaudy-Graffin et al., 2010). 
Moreover, the higher FRR found in this group of patients indicates that this assay can be only 
applied in viremic patients and it is not useful in HCV RNA-negative samples. This effect 
was also shown for HIV-recency assays where low viral loads (e.g. following treatment) are 
used to correct false recent classifications into long-term infections (Kassanjee et al., 2016).  
 
This study has certain limitations. Due to the relatively low number of samples in the sub-
panel of longitudinal DS/PS, MDRI across different genotypes was not calculated. Therefore, 
a larger sample size is required to obtain precise genotype specific MDRI estimates. However, 
as shown by FRR for genotype 1 infection, the assay performs well for the most prevalent 
genotype in Germany and can be applied in HCV RNA positive patients. The prolonged HCV 
seroconversion in HIV coinfected patients and its effect on MDRI estimate, FRR and FLTR 
should also be analyzed in a size adjusted sample set. It is imperative to note that the assay 
may not be used in clinical settings. However, its application as a tool for epidemiological 
studies is in our view of considerable importance.  
 
In conclusion, the described assay and protocol can be used for HCV-recency testing of 
DS/PS specimens from viremic infections. It performs with an accuracy of 86.9% with an AI 
cut off of 40%. Below this cut off the sample can be classified as acquired in less than a year 
with a FRR of 13.6%. At AI values above 40% the sample has to be classified as long 
standing with a FLTR of 5.9%. An important observation in our study, with relevance to HCV 
avidity determination in general, is the decline in the AI and the high FRR amongst resolved 
infections. It indicates that this group could be mistaken for recent infection and that viral 





5.3 DISCUSSION (PART III) 
This part of the study was the first extensive HCV screening of DSS from newly diagnosed 
HIV-infected patients in Germany. The aims of this study were to assess the prevalence of 
HCV infection among risk groups, to determine the HCV genotype/subtype distribution and 
to identify RAS that are relevant to DAA among newly HIV-diagnosed patients in Germany. 
For this purpose, 6,097 samples were serologically examined for HCV and the detected HCV 
infections were further characterized in terms of status (active/resolved), genotype/subtype 
distribution, DAA drug resistance and their relations with demographic characters.  
 
In the samples tested, a proportion of 6.5% were tested as HCV seropositive. According to the 
reports of WHO (WHO, 2017), 6.2% of people infected with HIV were additionally infected 
with HCV worldwide. The proportion of HCV seropositive persons detected in this study is, 
therefore, similar to the WHO data for the year 2015. Also, in this study, evidence of HCV 
RNA (active infection) was found in two thirds of HCV seropositive samples (overall 4.2%). 
In one third (overall 2.3%) antibodies against HCV were present, but no viral RNA was 
detected (resolved infection). The higher proportion of active infections in this study could be 
attributed to a less spontaneous clearance and a higher HCV viral load in HIV coinfection 
(Forns et al., 2017, Asselah et al., 2018).   
 
Between the diagnosis years 2015 and 2016, the proportions of HCV seropositive persons and 
active infections have non-significantly increased from 6.9% to 7.3% and from 4.2% to 5.4%, 
respectively. However, a significant decrease in the proportion of HCV seropositive (p<0.01) 
and active (viremic) infections (p<0.001) have been observed over the period 2016-2017. This 
was further demonstrated by a significant increase in the proportion of resolved infections 
(p<0.01) in the period 2016-2017 and in the post-DAA study implying the success of DAA 
therapy similar to studies elsewhere (Gomaa et al., 2017, Pradat et al., 2018, Iversen et al., 
2019). 
 
Although more than half (51.9%) of the participants in this study were MSM, the highest 
proportion of HCV seropositive cases were observed in the PWID group (77.8%). Also, 
according to the DRUCK study, 55.5% of HIV-infected PWIDs in Germany are 
simultaneously infected with HCV (Poethko-Muller et al., 2013). In PWIDs, infections with 
HIV and HCV are much more common than in the general population due to the sharing of 




many of the drug users don't know about their HCV status (Kwiatkowski et al., 2002) 
indicating that this important transmission group does not benefit so far from the new and 
efficient HCV treatment options to a similar extent as the other risk groups do. This 
necessitates more efforts for prevention, testing and treatment in this highly vulnerable part of 
the population. MSM represent the largest proportion of HIV new diagnoses in this study, but 
in only 2.5% of the cases could HCV be detected serologically. However, the data obtained 
here is lower when compared with the results of Jansen et al (Jansen et al., 2015) in which 
case they found 8.2% of the HIV positive MSM to be simultaneously infected with HCV in 
Germany. The decline observed in the current study could be attributed to the effectiveness of 
the new interferon-free DAA regimens after the year 2014/2015 in Germany.  
 
Although statistically non-significant, during the study period 2015-2016, an increase in the 
trend of HCV infection was observed in MSM. This increase parallels a number of other 
trends including increased sexual risk behaviors including serosorting that includes 
unprotected sex between men with the same HIV status and the use of “chemsex” drugs, 
including by injection (Bodsworth et al., 1996, Danta et al., 2008, Schnuriger et al., 2009, 
Thomson et al., 2009). A further characteristic of the increase in MSM is the alarming 
number of reinfections reported (Hagan et al., 2015). The increased proportion of HCV cases 
in PWIDs during the year 2016 (81%) might reflect the increased number of refugees and 
asylum seekers (Grote, 2018) which had a previous exposure to the virus and later diagnosed 
in Germany (Jablonka et al., 2017). However, during the year 2016-2017, a decrease in the 
proportion of HCV infection was noted in all transmission groups. A further reduction in the 
number of chronic HCV infections can be expected as antiviral treatment options improve 
(Sarrazin et al., 2012). The higher proportion of resolved infection in all transmission groups, 
in comparison with the pre-DAA study, reflects the positive impact of such treatments in 
these groups of patients.  
 
Analysis of recent and longstanding HIV/HCV coinfections using the established HCV 
recency assay has shown a higher proportion of HCV long-term in HIV long-term infections 
in all transmission groups and throughout the study period. This is due to the fact that HIV 
and HCV are transmitted in similar ways and, therefore, people who have HIV may be at 
higher risk of exposure to HCV (Hsieh et al., 2014). This study has also shown a significant 
increase (p<0.05) in the proportion of HCV recent in HIV recent infections in MSM 




positive MSM is high and it appears to be rapidly increasing over time (van der Helm et al., 
2011, Wandeler et al., 2012, Yaphe et al., 2012). Some of the reasons for this case are already 
mentioned in this part of the discussion.  
 
PWIDs were also observed to have a high proportion (35.5%) of HCV long-term infection in 
HIV recent cases and this has been almost similar in proportion across the diagnoses years of 
the study period. This is due to the fact that HCV infection is frequently asymptomatic and 
many of the PWIDs are not aware of their infection status and, hence, do not perform 
diagnosis or obtain treatment (Kwiatkowski et al., 2002). The report from WHO (WHO, 
2017) also shows that only a minority (20%) of the PWIDs with HCV had been tested and 
knew their status. On the other hand, earlier clinical detection of HIV compared to HCV due 
to its shorter latency until manifestations (Kim et al., 2013) could mean early diagnosis and a 
higher proportion of recent HIV cases in this transmission group.   
 
Among heterosexuals, the highest proportion (33.3%) of HCV recent infection in HIV long-
term infection was observed in the study cohort. Furthermore, in this group, the vast majority 
(74.3%) of the individuals were foreigners who have reported to have acquired the HIV 
infection in their country of origin (data not shown). Previous studies performed in Germany 
have also indicated that heterosexual persons who had originated abroad have long-term HIV 
infection than German natives (Hofmann et al., 2017). Most of these people might have 
acquired the infection in their country of origin and have later been diagnosed in Germany 
(Marcus and Starker, 2006). On the other hand, the finding of more recent HCV cases could 
be attributed to the fact that its transmission is not common in this group of patients. Evidence 
also shows a lower risk of sexual transmission among heterosexual couples in monogamous 
relationships (Tohme and Holmberg, 2010). The decrease in the proportion of recent HCV 
infection in recent HIV cases over the study period could also indicate the more regular and 
frequent testing of this transmission group over time.  
 
In this study, and also in the pre-DAA study, males contributed to a significantly higher 
proportion of HCV positive infections (72.8% and 78.3%, respectively). Also, the majority of 
the HCV coinfected males (78.4%) reported intravenous drug use as a means of transmission. 
A high prevalence of HIV/HCV coinfection among male PWIDs has been reported in various 
studies (Solomon et al., 2008, Mahanta et al., 2009, Panda et al., 2014, Saraswati et al., 




(44.2%). Other reports also show an association of HCV coinfection with higher rates of anti-
HCV antibodies among females engaged in higher-risk sexual practices (Gordon et al., 1992, 
Rosenberg, 1999, Minola et al., 2006). The increasing proportion of HCV coinfection among 
female PWIDs across the diagnoses years (2015-2017) could also be due to the overlapping 
sexual and injecting relationships with male PWID partners for resources such as drugs, 
injecting equipments and for physical safety and support that makes it more difficult for them 
to practice safe injecting in such context (Tracy et al., 2014). 
 
The trend in the proportion of resolved infections in males and females follows the trend in 
the total proportion of resolved infections, with an increase in the post-DAA group (p=0.17 
and p<0.05, respectively) and in the diagnosis year 2017 (p<0.05 and p=0.11, respectively) 
which again indicates the benefits of DAA therapy for both sex groups.     
 
The distribution of HCV infection in different age groups shows the highest proportion of 
infection in the age groups 30-39 (46%) and 40-49 (26.6%). This finding matches with the 
report of RKI (RKI, 2018) which has also shown a highest peak of infection in these age 
groups. The finding that these same age groups also have the highest proportion of PWIDs 
could further indicate the ongoing HCV infection in the middle age groups due to unsafe 
injection drug use (Mansberg et al., 2018). 
 
In comparison with the pre-DAA study, the proportions of HCV infection in this study 
showed a significant decline in the age groups 20-24 (p<0.05) and 25-29 (p<0.05) year olds. 
In a similar comparison, PWIDs of the same age groups have also shown a similar decrease in 
the proportion of HCV infection indicating the general decrease of HCV infection among the 
younger injection drug user population. On the other hand, the increase in the proportion of 
HCV infection in the age groups of 30-39 and 40-49 year olds points to an ongoing HCV 
infection in the middle age groups (Mansberg et al., 2018). However, the increase in the 
proportion of resolved infections in the age groups which have shown a higher proportion of 
HCV infection can be attributed to successful treatments of HCV in the country (Gomaa et 
al., 2017, Pradat et al., 2018, Iversen et al., 2019). 
 
Analysis of HCV infection by country of origin has shown that HCV infection is significantly 
higher in proportion among foreign nationals than Germans and the majority of the HCV 




This finding correlates with other studies which also showed HIV/HCV coinfection to be the 
most prevalent among PWIDs in these regions (Nelson et al., 2011, Platt et al., 2016). A 
study by Huppe et al (Huppe et al., 2008) also showed that, in Germany, immigration from 
Eastern Europe has contributed to the estimated 23–37% of HCV-infected persons of non-
German nationality. These data suggest that targeted screening programs may help in limiting 
the future health burden in these groups of population (Negro, 2014). 
 
In comparison with the data from the pre-DAA study, there has been an increase in the 
proportion of HCV infections in the overall foreign (p=0.61), Central Europe (p=0.71), 
Western Europe (p=0.27) and South/South East Asian (p=0.65) nationals. This indicates that 
there is still much to be accomplished in enhancing the rates of diagnosis and treatment to 
prevent disease transmission (Vermehren et al., 2018). However, the gradual decrease of 
HCV infection combined with the rise in the proportion of resolved infections among most 
nationalities during the course of the study period (2015-2017) can be attributed to the recent 
introduction of DAAs which made viral eradication possible in >95% of patients across 
different populations (Terrault, 2019).  
 
Analysis of HCV genotypes/subtypes has shown mainly subtypes 1a (33.9%), 3a (33.5%), 1b 
(22.3%) and 4d (3.9%). These subtypes are responsible for the majority of HCV cases 
worldwide (Weinbaum et al., 2005, Beijer et al., 2012) and in Western Europe (Petruzziello et 
al., 2016a). The order in the proportion of subtypes remained the same in the pre-DAA study 
and throughout the diagnoses years of the study period, except for the diagnosis year 2015 
where St-3a was the highest (39%) in proportion. It has been shown that the pattern of 
genotype and subtype distribution can be affected, among other things, by the nature of 
transmission and migration (Iversen et al., 2019). Therefore, the increased number of refugees 
and asylum seekers might have lead to this change in the pattern of subtype distribution in the 
diagnosis year 2015. 
 
When HCV subtypes are analyzed by the country of origin, a significant association (p<0.01) 
of subtype 1a with Germans was observed in this study. This is similar to other studies which 
also showed a relatively higher prevalence of this subtype in Germans (Berg et al., 1997) and 
Western Europeans (Robaeys et al., 2016). Moreover, this subtype is significantly associated 
with MSM (p<0.01) and, in comparison with the data from the pre-DAA study, its proportion 




1a was also observed among PWIDs in the pre-DAA study (40.9%) and in this study (33.6%). 
The high prevalence of subtype 1a among MSM was also observed in a study performed in 
HIV-negative MSM who started pre-exposure prophylaxis (PrEP) in Amsterdam 
(Hoornenborg et al., 2017) and in a community-recruited MSM in New York City (Tieu et al., 
2018). The association of subtype 1a with PWIDs has also been described in several studies 
(May et al., 2015b, Kartashev et al., 2016, Robaeys et al., 2016, Petruzziello et al., 2016a). 
 
In the current and pre-DAA studies, a higher proportion of subtype 3a (36.4% and 39.7%, 
respectively) was found in individuals with foreign origin. The association of subtype 3a with 
foreign nationals was particularly significant (p<0.01) in this study. In addition, both studies 
have shown highest frequencies (42.9% each) of subtype 3a in the PWIDs and heterosexuals, 
respectively. A similar predominance of subtype 3a in PWIDs has already been described in 
Germany and elsewhere (Berg et al., 1997, Petruzziello et al., 2013, Daw et al., 2015, 
Pawlotsky, 2016, Robaeys et al., 2016). The association of this subtype with foreign nationals 
and certain transmission groups could indicate its presumed correlation with active 
immigration from HCV endemic areas. 
 
In the pre-DAA study, subtype 4c was found to be common among individuals of German 
origin (9.5%). Although genotype 4 is traditionally associated to Central Africa and the 
Middle East (Mohd et al., 2013, Gower et al., 2014, Petruzziello et al., 2016b), some studies 
have shown that these genotypes are not uncommon within most European HCV centers 
(Gower et al., 2014). In this study, subtype 4c was reported to only be found in MSM (20%). 
This reflects the notion that the transmission of genotype 4 is mainly related to sexual 
practices, especially in MSM, and in HIV coinfected patients (Cornberg et al., 2011). In the 
current study, however, this subtype was not found in any of the study participants attributing 
to the efficiency of the DAAs against genotype 4 infections (Hathorn and Elsharkawy, 2016). 
 
Any amino acid substitution relative to the reference sequence at a position associated with 
decreased susceptibility to DAAs in vitro is generally defined as RAS (Bertoli et al., 2018). In 
HCV naturally occurring RAS are found with varying degrees of prevalence in the individual 
genotypes and subtypes. In addition, RAS may be due to the selection pressure of DAAs 





It is not known for the investigated samples whether and to what extent HCV therapy has 
already been performed. Accordingly, it cannot be assessed whether it is naturally occurring 
or if it is a drug-selected RAS. However, a comparison of the RAS prevalence in this study 
(2015: 69%, 2016: 60.8% and 2017: 56.4%) is comparable with a 51.4% of a naturally 
occurring RAS in HCV sequences of mainly DAA-naive persons in Europe (Chen et al., 
2016). The proportion of clinically relevant RAS (i.e. =RAS, which cause reduced efficacy or 
resistance to DAAs) in the study by Chen et al (2016) was 29.3%. The proportion of RAS 
with clinical relevance found in the samples tested here (2015: 28.5%, 2016: 35.4% and 2017: 
23.1%) are, therefore, at a comparable level.  
 
In the diagnoses years 2015, 2016 and 2017, the highest proportion of RAS was detected in 
genotype 1, especially in the NS3 region (Fig. 42). Frequent Q80K substitution is detected in 
4.8% to 75% of all subtype 1a infected individuals and leads to resistance to Simeprevir in 
vitro and in vivo (Sarrazin, 2016). The high proportion of samples with the Q80K substitution 
in our subtype 1a samples in the years of diagnosis 2015 (33.3%), 2016 (34.5%) and 2017 
(42.9%) thus meets the expectations. However, Simeprevir has not been available in Germany 
since May 2018, so the occurrence of this substitution has no effect on the regimen 
recommended for genotype 1 infections (Sarrazin et al., 2018). 
 
The natural occurrence of C316N and S556G substitution in the NS5B region in subtype 1b is 
described in the literature with a prevalence of up to 35.6% and 16%, respectively (Sarrazin, 
2016). With 12.5%-62.5% (C316N) and 23.8%-25% (S556G), a higher prevalence was found 
in the samples tested in this study. This could be explained by the unknown proportion of 
samples from DAA experienced individuals in whom these substitutions were highly selected. 
Although the C316N substitution alone has little effect on the efficacy of DAAs, the 
combination with the S556G mutation results in a higher resistance to Dasabuvir than does 
the S556G substitution alone (Jones et al., 2018). Overall, the data shows that the occurrence 
of RAS in genotype 1 does not generally lead to treatment failure and SVR is achieved in 
most cases of DAA initial therapy even without prior resistance testing (Sarrazin et al., 2018). 
 
In genotype 3 and genotype 4, only a few natural RAS are found overall (Sarrazin, 2016). In 
particular, the Y93H substitution in subtype 3a is associated with a decreased SVR rate 
(Sarrazin et al., 2018). Although this substitution is detected in the diagnosis year 2015 




In the samples examined, RAS were found predominantly in only one of three DAA-relevant 
genome regions. Especially in the St-1a and St-1b samples, however, a small proportion of 
samples were found with RAS in two or all three DAA-relevant genome regions. This can 
indicate a therapy failure with DAAs, since multiple RAS can be found in St-1a and St-1b 
samples from DAA therapy failures in particular (Di Maio et al., 2018). 
 
In conclusion, the proportion of HCV coinfections among newly diagnosed HIV cases in 
Germany is similar to the global coinfection prevalence (6.2%) reported by the WHO (WHO, 
2017). In comparison to the pre-DAA study and to the diagnoses years 2015-2016, the overall 
prevalence of HCV infections have shown a significant decline in the diagnosis year 2017. A 
further reduction in the number of chronic HCV infections can be expected as antiviral 
treatment options improve. However, the high prevalence of HCV coinfection in the middle 
age groups (30-39 and 40-49 years), in PWIDs and in people from Eastern and Central 
European regions dictates the need to enhance targeted screening programs and treatment to 
prevent further disease transmission among these groups of population. Furthermore, the 
increasing rate in the incidence of HCV infection observed in MSM suggests increased sexual 
risk behaviors which require more extensive risk behavior counseling and routine screening 
for HCV. Consistent with other reports in Europe (Petruzziello et al., 2016a), this study has 
found subtype 1a (33.9%) to be the most dominant, followed by subtype 3a (35.5%) and 
subtype 1b (22.3%) infections. However, the relative prevalence of subtypes changes in 
relation to the mode of transmission, country of origin and migration. In addition, the high 
proportion of resistance against DAAs in samples of subtypes 1a and 1b throughout the study 
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